Kari Alitalo

List of Publications by Year in Descending Order

726 papers	93,967 citations	159 h-index	282 g-index
748 ext. papers	101,732 ext. citations	10.7 avg, IF	7.87 L-index

#	Paper	IF	Citations
726	Interplay of vascular endothelial growth factor receptors in organ-specific vessel maintenance.. *Journal of Experimental Medicine*, **2022**, 219,	16.6	1
725	Significance of developmental meningeal lymphatic dysfunction in experimental post-traumatic injury. *Brain, Behavior, & Immunity - Health*, **2022**, 100466	5.1	
724	Cardiac-specific VEGFB overexpression reduces lipoprotein lipase activity and improves insulin action in rat heart. *American Journal of Physiology - Endocrinology and Metabolism*, **2021**, 321, E753-E765	6	0
723	Common Laboratory Mice Are Susceptible to Infection with the SARS-CoV-2 Beta Variant. *Viruses*, **2021**, 13,	6.2	1
722	Lef1 restricts ectopic crypt formation and tumor cell growth in intestinal adenomas. *Science Advances*, **2021**, 7, eabj0512	14.3	0
721	Lymphatic Malformations: Genetics, Mechanisms and Therapeutic Strategies. *Circulation Research*, **2021**, 129, 136-154	15.7	17
720	NOTUM from Apc-mutant cells biases clonal competition to initiate cancer. *Nature*, **2021**, 594, 430-435	50.4	31
719	Lysophosphatidylcholine in phospholipase A-modified LDL triggers secretion of angiopoietin 2. *Atherosclerosis*, **2021**, 327, 87-99	3.1	2
718	Counteracting age-related VEGF signaling insufficiency promotes healthy aging and extends life span. *Science*, **2021**, 373,	33.3	28
717	Pro-lymphangiogenic VEGFR-3 signaling modulates memory T cell responses in allergic airway inflammation. *Mucosal Immunology*, **2021**, 14, 144-151	9.2	2
716	Expression of R-Spondin 1 in Apc Mice Suppresses Growth of Intestinal Adenomas by Altering Wnt and Transforming Growth Factor Beta Signaling. *Gastroenterology*, **2021**, 160, 245-259	13.3	7
715	VEGF-B Promotes Endocardium-Derived Coronary Vessel Development and Cardiac Regeneration. *Circulation*, **2021**, 143, 65-77	16.7	18
714	3-hydroxy-L-kynurenamine is an immunomodulatory biogenic amine. *Nature Communications*, **2021**, 12, 4447	17.4	9
713	Blocking Angiopoietin-2 Promotes Vascular Damage and Growth Inhibition in Mouse Tumors Treated with Small Doses of Radiation. *Cancer Research*, **2020**, 80, 2639-2650	10.1	2
712	Lymphatic and Immune Cell Cross-Talk Regulates Cardiac Recovery After Experimental Myocardial Infarction. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2020**, 40, 1722-1737	9.4	23
711	Susceptibility to Cardiac Arrhythmias and Sympathetic Nerve Growth in VEGF-B Overexpressing Myocardium. *Molecular Therapy*, **2020**, 28, 1731-1740	11.7	10
710	Phase 1 Lymfactin Study: Short-term Safety of Combined Adenoviral VEGF-C and Lymph Node Transfer Treatment for Upper Extremity Lymphedema. *Journal of Plastic, Reconstructive and Aesthetic Surgery*, **2020**, 73, 1612-1621	1.7	16

709	Blockade of VEGF-C signaling inhibits lymphatic malformations driven by oncogenic PIK3CA mutation. *Nature Communications*, **2020**, 11, 2869	17.4	24
708	Lymphatic Vessels in Tumor Dissemination versus Immunotherapy. *Cancer Research*, **2020**, 80, 3463-3465	10.1	16
707	Platelet-Specific PDGFB Ablation Impairs Tumor Vessel Integrity and Promotes Metastasis. *Cancer Research*, **2020**, 80, 3345-3358	10.1	16
706	VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours. *Nature*, **2020**, 577, 689-694	50.4	154
705	Age-Dependent Remarkable Regenerative Potential of the Dentate Gyrus Provided by Intrinsic Stem Cells. *Journal of Neuroscience*, **2020**, 40, 974-995	6.6	8
704	Angiopoietin-2 blockade ameliorates autoimmune neuroinflammation by inhibiting leukocyte recruitment into the CNS. *Journal of Clinical Investigation*, **2020**, 130, 1977-1990	15.9	17
703	The GEF Trio controls endothelial cell size and arterial remodeling downstream of Vegf signaling in both zebrafish and cell models. *Nature Communications*, **2020**, 11, 5319	17.4	13
702	Distinct fibroblast subsets regulate lacteal integrity through YAP/TAZ-induced VEGF-C in intestinal villi. *Nature Communications*, **2020**, 11, 4102	17.4	8
701	VEGF-C protects the integrity of the bone marrow perivascular niche in mice. *Blood*, **2020**, 136, 1871-1883	22	14
700	Characterization of mutations associated with primary lymphedema. *Science Translational Medicine*, **2020**, 12,	17.5	15
699	Dural lymphatics regulate clearance of extracellular tau from the CNS. *Molecular Neurodegeneration*, **2019**, 14, 11	19	68
698	Endothelial Cells Regulate Physiological Cardiomyocyte Growth via VEGFR2-Mediated Paracrine Signaling. *Circulation*, **2019**, 139, 2570-2584	16.7	51
697	Systemic Blockade of ACVR2B Ligands Protects Myocardium from Acute Ischemia-Reperfusion Injury. *Molecular Therapy*, **2019**, 27, 600-610	11.7	16
696	High baseline Tie1 level predicts poor survival in metastatic breast cancer. *BMC Cancer*, **2019**, 19, 732	4.8	7
695	Anatomy and function of the vertebral column lymphatic network in mice. *Nature Communications*, **2019**, 10, 4594	17.4	43
694	Abstract 731: Sorafenib Induces Cardiotoxicity via Damage to Cardiac Endothelial Cells. *Circulation Research*, **2019**, 125,	15.7	1
693	Improved endothelialization of small-diameter ePTFE vascular grafts through growth factor therapy. *Vascular Biology (Bristol, England)*, **2019**, 1, 1-9	2.9	8
692	KLK3/PSA and cathepsin D activate VEGF-C and VEGF-D. *ELife*, **2019**, 8,	8.9	11

691	Gut microbiota regulates lacteal integrity by inducing VEGF-C in intestinal villus macrophages. *EMBO Reports*, **2019**, 20,	6.5	51
690	VEGFC Reduces Glomerular Albumin Permeability and Protects Against Alterations in VEGF Receptor Expression in Diabetic Nephropathy. *Diabetes*, **2019**, 68, 172-187	0.9	30
689	Genetic Variants of and Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib. *Cancer Research*, **2019**, 79, 231-241	10.1	9
688	Cardiac lymphatics in health and disease. *Nature Reviews Cardiology*, **2019**, 16, 56-68	14.8	64
687	Heterogeneity in VEGFR3 levels drives lymphatic vessel hyperplasia through cell-autonomous and non-cell-autonomous mechanisms. *Nature Communications*, **2018**, 9, 1296	17.4	28
686	Local adventitial anti-angiogenic gene therapy reduces growth of vasa-vasorum and in-stent restenosis in WHHL rabbits. *Journal of Molecular and Cellular Cardiology*, **2018**, 121, 145-154	5.8	11
685	VEGF-C promotes the development of lymphatics in bone and bone loss. *ELife*, **2018**, 7,	8.9	31
684	Vascular endothelial growth factor signaling in development and disease. *Development (Cambridge)* , **2018**, 145,	6.6	150
683	uPARAP/Endo180 receptor is a gatekeeper of VEGFR-2/VEGFR-3 heterodimerisation during pathological lymphangiogenesis. *Nature Communications*, **2018**, 9, 5178	17.4	10
682	Stimulation and Inhibition of Lymphangiogenesis Via Adeno-Associated Viral Gene Delivery. *Methods in Molecular Biology*, **2018**, 1846, 291-300	1.4	4
681	Mechanosensing by 1 integrin induces angiocrine signals for liver growth and survival. *Nature*, **2018**, 562, 128-132	50.4	71
680	Transcription Factor PROX1 Suppresses Notch Pathway Activation via the Nucleosome Remodeling and Deacetylase Complex in Colorectal Cancer Stem-like Cells. *Cancer Research*, **2018**, 78, 5820-5832	10.1	7
679	Consensus guidelines for the use and interpretation of angiogenesis assays. *Angiogenesis*, **2018**, 21, 425-532	10.2	285
678	PROX1 is a transcriptional regulator of MMP14. *Scientific Reports*, **2018**, 8, 9531	4.9	17
677	Structural basis of Tie2 activation and Tie2/Tie1 heterodimerization. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 4376-4381	11.5	45
676	Therapeutic targeting of the angiopoietin-TIE pathway. *Nature Reviews Drug Discovery*, **2017**, 16, 635-661	64.1	217
675	VEGFR2 but not VEGFR3 governs integrity and remodeling of thyroid angiofollicular unit in normal state and during goitrogenesis. *EMBO Molecular Medicine*, **2017**, 9, 750-769	12	13
674	Adventitial lymphatic capillary expansion impacts on plaque T cell accumulation in atherosclerosis. *Scientific Reports*, **2017**, 7, 45263	4.9	25

673	VEGFR3 Modulates Vascular Permeability by Controlling VEGF/VEGFR2 Signaling. *Circulation Research*, **2017**, 120, 1414-1425	15.7	71
672	SnapShot: Angiopoietins and Their Functions. *Cell*, **2017**, 171, 724-724.e1	56.2	20
671	Lymphangiogenesis guidance by paracrine and pericellular factors. *Genes and Development*, **2017**, 31, 1615-1634	12.6	87
670	Understanding the functions and relationships of the glymphatic system and meningeal lymphatics. *Journal of Clinical Investigation*, **2017**, 127, 3210-3219	15.9	284
669	Uncontrolled angiogenic precursor expansion causes coronary artery anomalies in mice lacking Pofut1. *Nature Communications*, **2017**, 8, 578	17.4	20
668	Midkine and Melanoma Metastasis: A Malevolent Mix. *Developmental Cell*, **2017**, 42, 205-207	10.2	4
667	Fighting vessel dysmorphia to improve glioma chemotherapy. *EMBO Molecular Medicine*, **2017**, 9, 1626-1628	12	1
666	Development and plasticity of meningeal lymphatic vessels. *Journal of Experimental Medicine*, **2017**, 214, 3645-3667	16.6	182
665	Retrograde Lymph Flow Leads to Chylothorax in Transgenic Mice with Lymphatic Malformations. *American Journal of Pathology*, **2017**, 187, 1984-1997	5.8	14
664	Efficient activation of the lymphangiogenic growth factor VEGF-C requires the C-terminal domain of VEGF-C and the N-terminal domain of CCBE1. *Scientific Reports*, **2017**, 7, 4916	4.9	49
663	White adipose tissue coloring by intermittent fasting. *Cell Research*, **2017**, 27, 1300-1301	24.7	3
662	Vascular Endothelial Growth Factor-B Induces a Distinct Electrophysiological Phenotype in Mouse Heart. *Frontiers in Physiology*, **2017**, 8, 373	4.6	2
661	The lymphatic system **2017**,		2
660	Functional Importance of a Proteoglycan Coreceptor in Pathologic Lymphangiogenesis. *Circulation Research*, **2016**, 119, 210-21	15.7	23
659	Elevated VEGF-D Modulates Tumor Inflammation and Reduces the Growth of Carcinogen-Induced Skin Tumors. *Neoplasia*, **2016**, 18, 436-46	6.4	10
658	Critical requirement of VEGF-C in transition to fetal erythropoiesis. *Blood*, **2016**, 128, 710-20	2.2	21
657	The transcription factor Prox1 is essential for satellite cell differentiation and muscle fibre-type regulation. *Nature Communications*, **2016**, 7, 13124	17.4	35
656	Transgenic overexpression of VEGF-C induces weight gain and insulin resistance in mice. *Scientific Reports*, **2016**, 6, 31566	4.9	22

655	VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 13144-13149	11.5	72
654	Lymphatic System in Cardiovascular Medicine. *Circulation Research*, **2016**, 118, 515-30	15.7	187
653	Simultaneous targeting of VEGF-receptors 2 and 3 with immunoliposomes enhances therapeutic efficacy. *Journal of Drug Targeting*, **2016**, 24, 80-9	5.4	13
652	Lymphatic vessels regulate immune microenvironments in human and murine melanoma. *Journal of Clinical Investigation*, **2016**, 126, 3389-402	15.9	120
651	Proteolytic activation defines distinct lymphangiogenic mechanisms for VEGFC and VEGFD. *Journal of Clinical Investigation*, **2016**, 126, 2167-80	15.9	68
650	Opposing actions of angiopoietin-2 on Tie2 signaling and FOXO1 activation. *Journal of Clinical Investigation*, **2016**, 126, 3511-25	15.9	119
649	Tie1 controls angiopoietin function in vascular remodeling and inflammation. *Journal of Clinical Investigation*, **2016**, 126, 3495-510	15.9	119
648	Angiopoietin receptor Tie2 is required for vein specification and maintenance via regulating COUP-TFII. *ELife*, **2016**, 5,	8.9	40
647	Ischemia-Reperfusion Injury Enhances Lymphatic Endothelial VEGFR3 and Rejection in Cardiac Allografts. *American Journal of Transplantation*, **2016**, 16, 1160-72	8.7	21
646	PROX1 and □catenin are prognostic markers in pancreatic ductal adenocarcinoma. *BMC Cancer*, **2016**, 16, 472	4.8	23
645	VEGFB/VEGFR1-Induced Expansion of Adipose Vasculature Counteracts Obesity and Related Metabolic Complications. *Cell Metabolism*, **2016**, 23, 712-24	24.6	122
644	Vascular endothelial growth factor receptor 3 controls neural stem cell activation in mice and humans. *Cell Reports*, **2015**, 10, 1158-72	10.6	49
643	State-of-the-Art Methods for Evaluation of Angiogenesis and Tissue Vascularization: A Scientific Statement From the American Heart Association. *Circulation Research*, **2015**, 116, e99-132	15.7	90
642	A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. *Journal of Experimental Medicine*, **2015**, 212, 991-9	16.6	1079
641	Growth factor therapy and lymph node graft for lymphedema. *Journal of Surgical Research*, **2015**, 196, 200-7	2.5	23
640	Donor Heart Treatment With COMP-Ang1 Limits Ischemia-Reperfusion Injury and Rejection of Cardiac Allografts. *American Journal of Transplantation*, **2015**, 15, 2075-84	8.7	15
639	Functional Dissection of the CCBE1 Protein: A Crucial Requirement for the Collagen Repeat Domain. *Circulation Research*, **2015**, 116, 1660-9	15.7	30
638	MMP16 Mediates a Proteolytic Switch to Promote Cell-Cell Adhesion, Collagen Alignment, and Lymphatic Invasion in Melanoma. *Cancer Research*, **2015**, 75, 2083-94	10.1	51

637	PROX1 is involved in progression of rectal neuroendocrine tumors, NETs. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2015**, 467, 279-84	5.1	8
636	Endothelial Bmx tyrosine kinase activity is essential for myocardial hypertrophy and remodeling. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 13063-8	11.5	23
635	Nonvenous origin of dermal lymphatic vasculature. *Circulation Research*, **2015**, 116, 1649-54	15.7	161
634	VEGF-C and VEGF-C156S in the pro-lymphangiogenic growth factor therapy of lymphedema: a large animal study. *Angiogenesis*, **2015**, 18, 313-26	10.6	51
633	Angiopoietin-2 blocking antibodies reduce early atherosclerotic plaque development in mice. *Atherosclerosis*, **2015**, 241, 297-304	3.1	37
632	VEGF-C is required for intestinal lymphatic vessel maintenance and lipid absorption. *EMBO Molecular Medicine*, **2015**, 7, 1418-25	12	116
631	Sufficient Evidence for Lymphatics in the Developing and Adult Human Choroid? **2015**, 56, 6709-10		12
630	cKit Lineage Hemogenic Endothelium-Derived Cells Contribute to Mesenteric Lymphatic Vessels. *Cell Reports*, **2015**, 10, 1708-1721	10.6	150
629	Assessment of tumour viability in human lung cancer xenografts with texture-based image analysis. *Journal of Clinical Pathology*, **2015**, 68, 614-21	3.9	8
628	Blockade of VEGF-C and VEGF-D modulates adipose tissue inflammation and improves metabolic parameters under high-fat diet. *Molecular Metabolism*, **2015**, 4, 93-105	8.8	68
627	Endothelial destabilization by angiopoietin-2 via integrin β1 activation. *Nature Communications*, **2015**, 6, 5962	17.4	158
626	VEGFR3 does not sustain retinal angiogenesis without VEGFR2. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 761-6	11.5	89
625	Intravital imaging of intestinal lacteals unveils lipid drainage through contractility. *Journal of Clinical Investigation*, **2015**, 125, 4042-52	15.9	61
624	Intestinal Commitment and Maturation of Human Pluripotent Stem Cells Is Independent of Exogenous FGF4 and R-spondin1. *PLoS ONE*, **2015**, 10, e0134551	3.7	17
623	The TIE Receptor Family **2015**, 743-775		3
622	VEGF-B-induced vascular growth leads to metabolic reprogramming and ischemia resistance in the heart. *EMBO Molecular Medicine*, **2014**, 6, 307-21	12	106
621	The sinus venosus contributes to coronary vasculature through VEGFC-stimulated angiogenesis. *Development (Cambridge)*, **2014**, 141, 4500-12	6.6	127
620	HIF-1α and HIF-2α induce angiogenesis and improve muscle energy recovery. *European Journal of Clinical Investigation*, **2014**, 44, 989-99	4.6	24

619	73: Parainflammation in cancer. *European Journal of Cancer*, **2014**, 50, S18	7.5	
618	Vascular endothelial growth factor-B in physiology and disease. *Physiological Reviews*, **2014**, 94, 779-94	47.9	98
617	Angiopoietin-2 inhibition prevents transplant ischemia-reperfusion injury and chronic rejection in rat cardiac allografts. *American Journal of Transplantation*, **2014**, 14, 1096-108	8.7	24
616	The impact of the receptor binding profiles of the vascular endothelial growth factors on their angiogenic features. *Biochimica Et Biophysica Acta - General Subjects*, **2014**, 1840, 454-63	4	23
615	Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy. *Journal of Clinical Investigation*, **2014**, 124, 824-34	15.9	58
614	Lack of cardiac and high-fat diet induced metabolic phenotypes in two independent strains of Vegf-b knockout mice. *Scientific Reports*, **2014**, 4, 6238	4.9	31
613	The Schlemm□s canal is a VEGF-C/VEGFR-3-responsive lymphatic-like vessel. *Journal of Clinical Investigation*, **2014**, 124, 3975-86	15.9	140
612	Lymphatic vessel insufficiency in hypercholesterolemic mice alters lipoprotein levels and promotes atherogenesis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2014**, 34, 1162-70	9.4	75
611	Oncogenic mutations in intestinal adenomas regulate Bim-mediated apoptosis induced by TGF-□ *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, E2229-36	11.5	42
610	Consensus statement on the immunohistochemical detection of ocular lymphatic vessels **2014**, 55, 6440-2		58
609	Pulmonary lymphangiectasia resulting from vascular endothelial growth factor-C overexpression during a critical period. *Circulation Research*, **2014**, 114, 806-22	15.7	47
608	CCBE1 enhances lymphangiogenesis via A disintegrin and metalloprotease with thrombospondin motifs-3-mediated vascular endothelial growth factor-C activation. *Circulation*, **2014**, 129, 1962-71	16.7	146
607	Prox1 promotes expansion of the colorectal cancer stem cell population to fuel tumor growth and ischemia resistance. *Cell Reports*, **2014**, 8, 1943-1956	10.6	46
606	The Prox1-Vegfr3 feedback loop maintains the identity and the number of lymphatic endothelial cell progenitors. *Genes and Development*, **2014**, 28, 2175-87	12.6	91
605	Angiopoietin 2 regulates the transformation and integrity of lymphatic endothelial cell junctions. *Genes and Development*, **2014**, 28, 1592-603	12.6	74
604	Lymphangiogenic factors, mechanisms, and applications. *Journal of Clinical Investigation*, **2014**, 124, 878-87	15.9	211
603	Lymphatic regulator PROX1 determines Schlemm□s canal integrity and identity. *Journal of Clinical Investigation*, **2014**, 124, 3960-74	15.9	110
602	VEGF-C and aortic cardiomyocytes guide coronary artery stem development. *Journal of Clinical Investigation*, **2014**, 124, 4899-914	15.9	64

601	A senescence-inflammatory switch from cancer-inhibitory to cancer-promoting mechanism. *Cancer Cell*, **2013**, 24, 242-56	24.3	164
600	Transgenic overexpression of interleukin-1□induces persistent lymphangiogenesis but not angiogenesis in mouse airways. *American Journal of Pathology*, **2013**, 182, 1434-47	5.8	35
599	The basis for the distinct biological activities of vascular endothelial growth factor receptor-1 ligands. *Science Signaling*, **2013**, 6, ra52	8.8	39
598	Neuropilin-2 and vascular endothelial growth factor receptor-3 are up-regulated in human vascular malformations. *Angiogenesis*, **2013**, 16, 137-46	10.6	19
597	VEGF-A regulated by progesterone governs uterine angiogenesis and vascular remodelling during pregnancy. *EMBO Molecular Medicine*, **2013**, 5, 1415-30	12	105
596	Ex vivo intracoronary gene transfer of adeno-associated virus 2 leads to superior transduction over serotypes 8 and 9 in rat heart transplants. *Transplant International*, **2013**, 26, 1126-37	3	7
595	Comparison of vascular growth factors in the murine brain reveals placenta growth factor as prime candidate for CNS revascularization. *Blood*, **2013**, 122, 658-65	2.2	26
594	Mouse models for studying angiogenesis and lymphangiogenesis in cancer. *Molecular Oncology*, **2013**, 7, 259-82	7.9	88
593	Interactions between VEGFR and Notch signaling pathways in endothelial and neural cells. *Cellular and Molecular Life Sciences*, **2013**, 70, 1779-92	10.3	58
592	A truncation allele in vascular endothelial growth factor c reveals distinct modes of signaling during lymphatic and vascular development. *Development (Cambridge)*, **2013**, 140, 1497-506	6.6	79
591	Preclinical safety, toxicology, and biodistribution study of adenoviral gene therapy with sVEGFR-2 and sVEGFR-3 combined with chemotherapy for ovarian cancer. *Human Gene Therapy Clinical Development*, **2013**, 24, 29-37	3.2	9
590	Increased interstitial protein because of impaired lymph drainage does not induce fibrosis and inflammation in lymphedema. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2013**, 33, 266-74	9.4	22
589	The parallel growth of motoneuron axons with the dorsal aorta depends on Vegfc/Vegfr3 signaling in zebrafish. *Development (Cambridge)*, **2013**, 140, 4081-90	6.6	26
588	A novel multistep mechanism for initial lymphangiogenesis in mouse embryos based on ultramicroscopy. *EMBO Journal*, **2013**, 32, 629-44	13	207
587	Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 12960-5	11.5	61
586	Immune cells control skin lymphatic electrolyte homeostasis and blood pressure. *Journal of Clinical Investigation*, **2013**, 123, 2803-15	15.9	253
585	Activation of hypoxia response in endothelial cells contributes to ischemic cardioprotection. *Molecular and Cellular Biology*, **2013**, 33, 3321-9	4.8	38
584	Receptor tyrosine kinase-mediated angiogenesis. *Cold Spring Harbor Perspectives in Biology*, **2013**, 5,	10.2	104

583	PHD2 regulates arteriogenic macrophages through TIE2 signalling. *EMBO Molecular Medicine*, **2013**, 5, 843-57	12	35
582	Vascular endothelial growth factor-angiopoietin chimera with improved properties for therapeutic angiogenesis. *Circulation*, **2013**, 127, 424-34	16.7	47
581	Lymph node transfer and perinodal lymphatic growth factor treatment for lymphedema. *Annals of Surgery*, **2013**, 257, 961-7	7.8	67
580	Aberrant mural cell recruitment to lymphatic vessels and impaired lymphatic drainage in a murine model of pulmonary fibrosis. *Blood*, **2012**, 119, 5931-42	2.2	31
579	PV-1 is recognized by the PAL-E antibody and forms complexes with NRP-1. *Blood*, **2012**, 120, 232-5	2.2	15
578	Gene-targeting of Phd2 improves tumor response to chemotherapy and prevents side-toxicity. *Cancer Cell*, **2012**, 22, 263-77	24.3	101
577	A radical view of pathological vasculature. *Cell Metabolism*, **2012**, 16, 287-8	24.6	3
576	AAV9-mediated VEGF-B gene transfer improves systolic function in progressive left ventricular hypertrophy. *Molecular Therapy*, **2012**, 20, 2212-21	11.7	50
575	Antiangiogenic gene therapy with soluble VEGF-receptors -1, -2 and -3 together with paclitaxel prolongs survival of mice with human ovarian carcinoma. *International Journal of Cancer*, **2012**, 131, 2394-401	7.5	15
574	Thermodynamic and structural description of allosterically regulated VEGFR-2 dimerization. *Blood*, **2012**, 119, 1781-8	2.2	83
573	Ligand oligomerization state controls Tie2 receptor trafficking and angiopoietin-2-specific responses. *Journal of Cell Science*, **2012**, 125, 2212-23	5.3	21
572	Deletion of the endothelial Bmx tyrosine kinase decreases tumor angiogenesis and growth. *Cancer Research*, **2012**, 72, 3512-21	10.1	29
571	Impaired humoral immunity and tolerance in K14-VEGFR-3-Ig mice that lack dermal lymphatic drainage. *Journal of Immunology*, **2012**, 189, 2181-90	5.3	91
570	Induced pluripotent stem cell clones reprogrammed via recombinant adeno-associated virus-mediated transduction contain integrated vector sequences. *Journal of Virology*, **2012**, 86, 4463-7	6.6	17
569	In vivo imaging of lymphatic vessels in development, wound healing, inflammation, and tumor metastasis. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 6223-8	11.5	92
568	Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis. *Journal of the National Cancer Institute*, **2012**, 104, 461-75	9.7	158
567	Essential role of the coxsackie- and adenovirus receptor (CAR) in development of the lymphatic system in mice. *PLoS ONE*, **2012**, 7, e37523	3.7	35
566	Blocking Fibroblast Growth Factor receptor signaling inhibits tumor growth, lymphangiogenesis, and metastasis. *PLoS ONE*, **2012**, 7, e39540	3.7	28

565	Angiopoietin-like 4 mediates PPAR delta effect on lipoprotein lipase-dependent fatty acid uptake but not on beta-oxidation in myotubes. *PLoS ONE*, **2012**, 7, e46212	3.7	40
564	The lymphatic vasculature in disease. *Nature Medicine*, **2011**, 17, 1371-80	50.5	643
563	Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis. *Nature*, **2011**, 479, 122-6	50.4	237
562	Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer. *Molecular Cancer*, **2011**, 10, 36	42.1	66
561	KSHV-initiated notch activation leads to membrane-type-1 matrix metalloproteinase-dependent lymphatic endothelial-to-mesenchymal transition. *Cell Host and Microbe*, **2011**, 10, 577-90	23.4	96
560	Expression and prognostic value of transcription factor PROX1 in colorectal cancer. *British Journal of Cancer*, **2011**, 105, 1346-51	8.7	37
559	VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. *Trends in Molecular Medicine*, **2011**, 17, 347-62	11.5	334
558	VEGF mediates commissural axon chemoattraction through its receptor Flk1. *Neuron*, **2011**, 70, 966-78	13.9	113
557	Vascular endothelial growth factor C acts as a neurotrophic factor for dopamine neurons in vitro and in vivo. *Neuroscience*, **2011**, 192, 550-63	3.9	28
556	Cotargeting of VEGFR-1 and -3 and angiopoietin receptor Tie2 reduces the growth of solid human ovarian cancer in mice. *Cancer Gene Therapy*, **2011**, 18, 100-9	5.4	12
555	Photodynamic ablation of lymphatic vessels and intralymphatic cancer cells prevents metastasis. *Science Translational Medicine*, **2011**, 3, 69ra11	17.5	84
554	VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling. *Nature Cell Biology*, **2011**, 13, 1202-13	23.4	237
553	Fifteen years of molecular lymphangiogenesis - an interview with Kari Alitalo by Tatiana Petrova. *International Journal of Developmental Biology*, **2011**, 55, 389-94	1.9	1
552	Zebrafish Tie-2 shares a redundant role with Tie-1 in heart development and regulates vessel integrity. *DMM Disease Models and Mechanisms*, **2011**, 4, 57-66	4.1	46
551	Structural determinants of vascular endothelial growth factor-D receptor binding and specificity. *Blood*, **2011**, 117, 1507-15	2.2	66
550	An important role of lymphatic vessel activation in limiting acute inflammation. *Blood*, **2011**, 117, 4667-78	8.2	183
549	CKIablation highlights a critical role for p53 in invasiveness control. *Nature*, **2011**, 470, 409-13	50.4	149
548	Copy number variation and selection during reprogramming to pluripotency. *Nature*, **2011**, 471, 58-62	50.4	753

547	Perspectives on lymphangiogenesis and angiogenesis in cancer. *Journal of Surgical Oncology*, **2011**, 103, 484-8	2.8	30
546	Growth factor therapy and autologous lymph node transfer in lymphedema. *Circulation*, **2011**, 123, 613-20	16.7	135
545	Vascular endothelial growth factor receptor 3 directly regulates murine neurogenesis. *Genes and Development*, **2011**, 25, 831-44	12.6	107
544	Notch restricts lymphatic vessel sprouting induced by vascular endothelial growth factor. *Blood*, **2011**, 118, 1154-62	2.2	97
543	The tyrosine kinase BMX is an essential mediator of inflammatory arthritis in a kinase-independent manner. *Journal of Immunology*, **2011**, 186, 6014-23	5.3	26
542	Structural analysis of vascular endothelial growth factor receptor-2/ligand complexes by small-angle X-ray solution scattering. *FASEB Journal*, **2011**, 25, 2980-6	0.9	31
541	Biological basis of therapeutic lymphangiogenesis. *Circulation*, **2011**, 123, 1335-51	16.7	119
540	Roles of prostaglandin E2-EP3/EP4 receptor signaling in the enhancement of lymphangiogenesis during fibroblast growth factor-2-induced granulation formation. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2011**, 31, 1049-58	9.4	49
539	Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. *Journal of Clinical Investigation*, **2011**, 121, 2000-12	15.9	137
538	The yin, the yang, and the angiopoietin-1. *Journal of Clinical Investigation*, **2011**, 121, 2157-9	15.9	39
537	Zebrafish Tie-2 shares a redundant role with Tie-1 in heart development and regulates vessel integrity. *Development (Cambridge)*, **2011**, 138, e0407-e0407	6.6	0
536	VEGF receptor 2/-3 heterodimers detected in situ by proximity ligation on angiogenic sprouts. *EMBO Journal*, **2010**, 29, 1377-88	13	134
535	Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis. *PLoS ONE*, **2010**, 5, e14109	3.7	40
534	Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3. *Journal of Cell Biology*, **2010**, 188, 115-30	7.3	246
533	Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation. *Journal of Experimental Medicine*, **2010**, 207, 2255-69	16.6	181
532	Claudin-like protein 24 interacts with the VEGFR-2 and VEGFR-3 pathways and regulates lymphatic vessel development. *Genes and Development*, **2010**, 24, 875-80	12.6	29
531	CXCR4 signaling regulates metastasis of chemoresistant melanoma cells by a lymphatic metastatic niche. *Cancer Research*, **2010**, 70, 10411-21	10.1	135
530	Fibroblast growth factor receptor 4 regulates tumor invasion by coupling fibroblast growth factor signaling to extracellular matrix degradation. *Cancer Research*, **2010**, 70, 7851-61	10.1	39

529	Targeting lymphatic vessel activation and CCL21 production by vascular endothelial growth factor receptor-3 inhibition has novel immunomodulatory and antiarteriosclerotic effects in cardiac allografts. *Circulation*, **2010**, 121, 1413-22	16.7	105
528	FGF receptor-4 (FGFR4) polymorphism acts as an activity switch of a membrane type 1 matrix metalloproteinase-FGFR4 complex. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 15786-91	11.5	41
527	Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. *Circulation*, **2010**, 122, 1725-33	16.7	113
526	Loss of endothelial Tie1 receptor impairs lymphatic vessel development-brief report. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2010**, 30, 207-9	9.4	59
525	Structural determinants of growth factor binding and specificity by VEGF receptor 2. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 2425-30	11.5	134
524	Cardiomyocyte-targeted HIF-1alpha gene therapy inhibits cardiomyocyte apoptosis and cardiac allograft vasculopathy in the rat. *Journal of Heart and Lung Transplantation*, **2010**, 29, 1058-66	5.8	11
523	Lymphangiogenesis: Molecular mechanisms and future promise. *Cell*, **2010**, 140, 460-76	56.2	988
522	Dermal collagen and lipid deposition correlate with tissue swelling and hydraulic conductivity in murine primary lymphedema. *American Journal of Pathology*, **2010**, 176, 1122-9	5.8	69
521	Akt/Protein kinase B is required for lymphatic network formation, remodeling, and valve development. *American Journal of Pathology*, **2010**, 177, 2124-33	5.8	77
520	Liprin (beta)1 is highly expressed in lymphatic vasculature and is important for lymphatic vessel integrity. *Blood*, **2010**, 115, 906-9	2.2	35
519	Novel function for blood platelets and podoplanin in developmental separation of blood and lymphatic circulation. *Blood*, **2010**, 115, 3997-4005	2.2	239
518	Role of synectin in lymphatic development in zebrafish and frogs. *Blood*, **2010**, 116, 3356-66	2.2	33
517	Inside bloody lymphatics. *Blood*, **2010**, 116, 512-3	2.2	5
516	Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization. *Cancer Cell*, **2010**, 18, 630-40	24.3	108
515	Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. *Genes Chromosomes and Cancer*, **2010**, 49, 1062-9	5	161
514	Embryonic vascular endothelial cells are malleable to reprogramming via Prox1 to a lymphatic gene signature. *BMC Developmental Biology*, **2010**, 10, 72	3.1	37
513	Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3. *Journal of Experimental Medicine*, **2010**, 207, i1-i1	16.6	2
512	How do angiopoietins Tie in with vascular endothelial growth factors?. *Current Opinion in Hematology*, **2010**, 17, 198-205	3.3	66

511	Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation. *Journal of Cell Biology*, **2010**, 190, i14-i14	7.3	
510	Vascular endothelial growth factor-B induces myocardium-specific angiogenesis and arteriogenesis via vascular endothelial growth factor receptor-1- and neuropilin receptor-1-dependent mechanisms. *Circulation*, **2009**, 119, 845-56	16.7	143
509	FOXC2 controls formation and maturation of lymphatic collecting vessels through cooperation with NFATc1. *Journal of Cell Biology*, **2009**, 185, 439-57	7.3	254
508	Angiopoietin-1 overexpression modulates vascular endothelium to facilitate tumor cell dissemination and metastasis establishment. *Cancer Research*, **2009**, 69, 4656-64	10.1	52
507	Activated forms of VEGF-C and VEGF-D provide improved vascular function in skeletal muscle. *Circulation Research*, **2009**, 104, 1302-12	15.7	81
506	Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice. *Molecular Therapy*, **2009**, 17, 278-84	11.7	38
505	PDGF-A, -C, and -D but not PDGF-B increase TGF-beta1 and chronic rejection in rat cardiac allografts. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2009**, 29, 691-8	9.4	38
504	Vegfc/Flt4 signalling is suppressed by Dll4 in developing zebrafish intersegmental arteries. *Development (Cambridge)*, **2009**, 136, 4001-9	6.6	175
503	New approaches to pathogenesis and management of hypertension. *Clinical Journal of the American Society of Nephrology: CJASN*, **2009**, 4, 1886-91	6.9	2
502	VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. *Current Opinion in Cell Biology*, **2009**, 21, 154-65	9	551
501	Organ-specific lymphangiectasia, arrested lymphatic sprouting, and maturation defects resulting from gene-targeting of the PI3K regulatory isoforms p85alpha, p55alpha, and p50alpha. *Developmental Dynamics*, **2009**, 238, 2670-9	2.9	49
500	Functional analysis of FLT4 mutations associated with Nonne-Milroy lymphedema. *Journal of Investigative Dermatology*, **2009**, 129, 509-12	4.3	4
499	Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism. *Nature Medicine*, **2009**, 15, 545-52	50.5	667
498	Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. *Nature Reviews Molecular Cell Biology*, **2009**, 10, 165-77	48.7	1051
497	Recessive primary congenital lymphoedema caused by a VEGFR3 mutation. *Journal of Medical Genetics*, **2009**, 46, 399-404	5.8	49
496	Critical role of CD11b+ macrophages and VEGF in inflammatory lymphangiogenesis, antigen clearance, and inflammation resolution. *Blood*, **2009**, 113, 5650-9	2.2	295
495	Lymphangiogenesis in Health and Disease An Overview. *Cancer Metastasis - Biology and Treatment* , **2009**, 1-9		
494	Molecular Targeting of Lymphangiogenesis and Tumor Metastasis **2009**, 283-295		

493	FOXC2 controls formation and maturation of lymphatic collecting vessels through cooperation with NFATc1. *Journal of Experimental Medicine*, **2009**, 206, i10-i10	16.6	
492	Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. *Nature*, **2008**, 454, 656-60	50.4	649
491	Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts. *Nature Cell Biology*, **2008**, 10, 527-37	23.4	348
490	Modeling lymphangiogenesis in a three-dimensional culture system. *Nature Methods*, **2008**, 5, 431-7	21.6	97
489	Transcription factor PROX1 induces colon cancer progression by promoting the transition from benign to highly dysplastic phenotype. *Cancer Cell*, **2008**, 13, 407-19	24.3	140
488	VEGFR-3 expression is restricted to blood and lymphatic vessels in solid tumors. *Cancer Cell*, **2008**, 13, 554-6	24.3	73
487	Prox1 interacts with Atoh1 and Gfi1, and regulates cellular differentiation in the inner ear sensory epithelia. *Developmental Biology*, **2008**, 322, 33-45	3.1	53
486	Molecular biology and pathology of lymphangiogenesis. *Annual Review of Pathology: Mechanisms of Disease*, **2008**, 3, 367-97	34	264
485	Transgenic induction of vascular endothelial growth factor-C is strongly angiogenic in mouse embryos but leads to persistent lymphatic hyperplasia in adult tissues. *American Journal of Pathology*, **2008**, 173, 1891-901	5.8	64
484	The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. *Cancer Research*, **2008**, 68, 4754-62	10.1	96
483	Essential roles for the Tec family kinases Tec and Btk in M-CSF receptor signaling pathways that regulate macrophage survival. *Journal of Immunology*, **2008**, 180, 8048-56	5.3	46
482	Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. *Cancer Research*, **2008**, 68, 7828-37	10.1	132
481	Vascular endothelial growth factor-A and platelet-derived growth factor-B combination gene therapy prolongs angiogenic effects via recruitment of interstitial mononuclear cells and paracrine effects rather than improved pericyte coverage of angiogenic vessels. *Circulation Research*, **2008**, 103, 1092-9	15.7	62
480	VEGF-C induced angiogenesis preferentially occurs at a distance from lymphangiogenesis. *Cardiovascular Research*, **2008**, 78, 315-23	9.9	54
479	Reply to Kerbel et al.: EPCs are again claimed to be essential in yet other models despite the irreproducibility of the original experiments introducing them. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, E55-E55	11.5	5
478	Deletion of vascular endothelial growth factor C (VEGF-C) and VEGF-D is not equivalent to VEGF receptor 3 deletion in mouse embryos. *Molecular and Cellular Biology*, **2008**, 28, 4843-50	4.8	153
477	Overexpression of vascular endothelial growth factor-B in mouse heart alters cardiac lipid metabolism and induces myocardial hypertrophy. *Circulation Research*, **2008**, 103, 1018-26	15.7	107
476	Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2008**, 28, 1614-20	9.4	92

475	Loss of Bmx nonreceptor tyrosine kinase prevents pressure overload-induced cardiac hypertrophy. *Circulation Research*, **2008**, 103, 1359-62	15.7	28
474	Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b+ macrophages in advanced ovarian cancer. *Cancer Research*, **2008**, 68, 1100-9	10.1	106
473	Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 6620-5	11.5	340
472	VEGF-D: a modifier of embryonic lymphangiogenesis. *Blood*, **2008**, 112, 1547-8	2.2	5
471	Molecular Players in Lymphangiogenesis **2008**, 325-340		
470	Angiopoietins and Tie Receptors **2008**, 113-120		0
469	Molecular pathways for lymphangiogenesis and their role in human disease. *Novartis Foundation Symposium*, **2007**, 281, 38-43; discussion 44-53, 208-9		14
468	Modulating metastasis by a lymphangiogenic switch in prostate cancer. *International Journal of Cancer*, **2007**, 121, 2153-61	7.5	49
467	Therapeutic differentiation and maturation of lymphatic vessels after lymph node dissection and transplantation. *Nature Medicine*, **2007**, 13, 1458-66	50.5	274
466	Molecular regulation of angiogenesis and lymphangiogenesis. *Nature Reviews Molecular Cell Biology*, **2007**, 8, 464-78	48.7	1445
465	On the relationship of LDL and VEGFR1: not just a family affair. *EMBO Reports*, **2007**, 8, 1127-8	6.5	3
464	Lymphangiogenesis in development and human disease. *Experimental Dermatology*, **2007**, 16, 863-864	4	
463	Proprotein convertases promote processing of VEGF-D, a critical step for binding the angiogenic receptor VEGFR-2. *FASEB Journal*, **2007**, 21, 1088-98	0.9	92
462	Transcriptomal comparison of human dermal lymphatic endothelial cells ex vivo and in vitro. *Physiological Genomics*, **2007**, 28, 179-92	3.6	85
461	Viral oncogene-induced DNA damage response is activated in Kaposi sarcoma tumorigenesis. *PLoS Pathogens*, **2007**, 3, 1348-60	7.6	85
460	Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. *Cancer Research*, **2007**, 67, 593-9	10.1	195
459	VEGFR-1 and -2 regulate inflammation, myocardial angiogenesis, and arteriosclerosis in chronically rejecting cardiac allografts. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2007**, 27, 819-25	9.4	19
458	Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice. *Cancer Research*, **2007**, 67, 11528-35	10.1	102

457	Distinct architecture of lymphatic vessels induced by chimeric vascular endothelial growth factor-C/vascular endothelial growth factor heparin-binding domain fusion proteins. *Circulation Research*, **2007**, 100, 1468-75	15.7	32
456	Enhanced capillary formation stimulated by a chimeric vascular endothelial growth factor/vascular endothelial growth factor-C silk domain fusion protein. *Circulation Research*, **2007**, 100, 1460-7	15.7	12
455	Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting. *Journal of Experimental Medicine*, **2007**, 204, 1431-40	16.6	137
454	Lymphangiogenesis in development and disease. *Novartis Foundation Symposium*, **2007**, 283, 87-98; discussion 98-105, 238-41		12
453	Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. *Cell*, **2007**, 129, 957-68	56.2	480
452	The VEGF family, the inside story. *Cell*, **2007**, 130, 591-2	56.2	35
451	Distinct roles of vascular endothelial growth factor-D in lymphangiogenesis and metastasis. *American Journal of Pathology*, **2007**, 170, 1348-61	5.8	109
450	VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. *Blood*, **2007**, 109, 1010-7	2.2	410
449	Moderate antiangiogenic activity by local, transgenic expression of endostatin in Rip1Tag2 transgenic mice. *Journal of Leukocyte Biology*, **2006**, 80, 669-76	6.5	2
448	Chimeric VEGF-E(NZ7)/PlGF promotes angiogenesis via VEGFR-2 without significant enhancement of vascular permeability and inflammation. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2006**, 26, 2019-26	9.4	38
447	Vascular endothelial growth factor (VEGF)/VEGF-C mosaic molecules reveal specificity determinants and feature novel receptor binding patterns. *Journal of Biological Chemistry*, **2006**, 281, 12187-95	5.4	29
446	Common protective and diverse smooth muscle cell effects of AAV-mediated angiopoietin-1 and -2 expression in rat cardiac allograft vasculopathy. *Circulation Research*, **2006**, 98, 1373-80	15.7	32
445	Pulmonary vascular endothelial growth factor-C in development and lung injury in preterm infants. *American Journal of Respiratory and Critical Care Medicine*, **2006**, 174, 326-30	10.2	27
444	Signaling and functions of angiopoietin-1 in vascular protection. *Circulation Research*, **2006**, 98, 1014-23	15.7	321
443	Lymphangiogenic growth factor responsiveness is modulated by postnatal lymphatic vessel maturation. *American Journal of Pathology*, **2006**, 169, 708-18	5.8	118
442	Vascular endothelial growth factor-C accelerates diabetic wound healing. *American Journal of Pathology*, **2006**, 169, 1080-7	5.8	168
441	Early lymph vessel development from embryonic stem cells. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2006**, 26, 1073-8	9.4	48
440	Functional interaction of VEGF-C and VEGF-D with neuropilin receptors. *FASEB Journal*, **2006**, 20, 1462-72	2.9	237

439	Vascular endothelial growth factor C-induced collateral formation in a model of myocardial ischemia. *Journal of Heart and Lung Transplantation*, **2006**, 25, 206-13	5.8	28
438	The effect of platelet-derived growth factor ligands in rat cardiac allograft vasculopathy and fibrosis. *Transplantation Proceedings*, **2006**, 38, 3271-3	1.1	13
437	Yet another function for hepatocyte growth factor. *Blood*, **2006**, 107, 3424-3425	2.2	1
436	VEGF-C is a trophic factor for neural progenitors in the vertebrate embryonic brain. *Nature Neuroscience*, **2006**, 9, 340-8	25.5	144
435	Large-scale identification of genes implicated in kidney glomerulus development and function. *EMBO Journal*, **2006**, 25, 1160-74	13	172
434	Transcapillary fluid balance consequences of missing initial lymphatics studied in a mouse model of primary lymphoedema. *Journal of Physiology*, **2006**, 574, 583-96	3.9	34
433	Critical function of Bmx/Etk in ischemia-mediated arteriogenesis and angiogenesis. *Journal of Clinical Investigation*, **2006**, 116, 2344-55	15.9	64
432	Short and long-term effects of hVEGF-A(165) in Cre-activated transgenic mice. *PLoS ONE*, **2006**, 1, e13	3.7	15
431	The lymphatic vasculature: recent progress and paradigms. *Annual Review of Cell and Developmental Biology*, **2005**, 21, 457-83	12.6	179
430	Multiple angiopoietin recombinant proteins activate the Tie1 receptor tyrosine kinase and promote its interaction with Tie2. *Journal of Cell Biology*, **2005**, 169, 239-43	7.3	166
429	Endostatin signaling and regulation of endothelial cell-matrix interactions. *Advances in Cancer Research*, **2005**, 94, 197-229	5.9	41
428	PDZ interaction site in ephrinB2 is required for the remodeling of lymphatic vasculature. *Genes and Development*, **2005**, 19, 397-410	12.6	357
427	Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation. *Blood*, **2005**, 105, 4649-56	2.2	202
426	Angiopoietin-1 promotes lymphatic sprouting and hyperplasia. *Blood*, **2005**, 105, 4642-8	2.2	204
425	Lymphangiogenesis in development and human disease. *Nature*, **2005**, 438, 946-53	50.4	952
424	Molecular lymphangiogenesis: new players. *Trends in Cell Biology*, **2005**, 15, 434-41	18.3	108
423	Contribution of bone marrow-derived pericyte precursor cells to corneal vasculogenesis. *Investigative Ophthalmology and Visual Science*, **2005**, 46, 3502-6		69
422	Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. *Cancer Research*, **2005**, 65, 6901-9	10.1	210

421	Neural guidance molecules regulate vascular remodeling and vessel navigation. *Genes and Development*, **2005**, 19, 1013-21	12.6	193
420	Gene transfers of vascular endothelial growth factor-A, vascular endothelial growth factor-B, vascular endothelial growth factor-C, and vascular endothelial growth factor-D have no effects on atherosclerosis in hypercholesterolemic low-density lipoprotein-receptor/apolipoprotein B48-deficient mice. *Circulation*, **2005**, 112, 1347-52	16.7	71
419	Activation of hypoxia-inducible factor-1 in bacillary angiomatosis: evidence for a role of hypoxia-inducible factor-1 in bacterial infections. *Circulation*, **2005**, 111, 1054-62	16.7	124
418	Stabilized HIF-1alpha is superior to VEGF for angiogenesis in skeletal muscle via adeno-associated virus gene transfer. *FASEB Journal*, **2005**, 19, 1365-7	0.9	109
417	Periadventitial angiopoietin-1 gene transfer induces angiogenesis in rabbit carotid arteries. *Gene Therapy*, **2005**, 12, 388-94	4	16
416	The biology of vascular endothelial growth factors. *Cardiovascular Research*, **2005**, 65, 550-63	9.9	557
415	Adenovirus-mediated gene transfer of placental growth factor to perivascular tissue induces angiogenesis via upregulation of the expression of endogenous vascular endothelial growth factor-A. *Human Gene Therapy*, **2005**, 16, 1422-8	4.8	50
414	Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. *Cancer Research*, **2005**, 65, 4739-46	10.1	332
413	Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. *Journal of Clinical Investigation*, **2005**, 115, 247-257	15.9	434
412	Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. *Journal of Clinical Investigation*, **2005**, 115, 247-57	15.9	268
411	Adenovirus-Mediated Gene Transfer of Placental Growth Factor to Perivascular Tissue Induces Angiogenesis via Upregulation of the Expression of Endogenous Vascular Endothelial Growth Factor-A. *Human Gene Therapy*, **2005**, 051114062912001	4.8	
410	Bmx tyrosine kinase transgene induces skin hyperplasia, inflammatory angiogenesis, and accelerated wound healing. *Molecular Biology of the Cell*, **2004**, 15, 4226-33	3.5	31
409	Loss of neural cell adhesion molecule induces tumor metastasis by up-regulating lymphangiogenesis. *Cancer Research*, **2004**, 64, 8630-8	10.1	74
408	Vascular endothelial growth factor receptor-3 in hypoxia-induced vascular development. *FASEB Journal*, **2004**, 18, 1507-15	0.9	39
407	Oral imatinib mesylate (STI571/gleevec) improves the efficacy of local intravascular vascular endothelial growth factor-C gene transfer in reducing neointimal growth in hypercholesterolemic rabbits. *Circulation*, **2004**, 109, 1140-6	16.7	43
406	Preexisting lymphatic endothelium but not endothelial progenitor cells are essential for tumor lymphangiogenesis and lymphatic metastasis. *Cancer Research*, **2004**, 64, 3737-40	10.1	152
405	Specific induction of tie1 promoter by disturbed flow in atherosclerosis-prone vascular niches and flow-obstructing pathologies. *Circulation Research*, **2004**, 94, 394-401	15.7	71
404	Vascular endothelial growth factor-C gene therapy restores lymphatic flow across incision wounds. *FASEB Journal*, **2004**, 18, 1707-9	0.9	83

403	Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability. *Circulation Research*, **2004**, 94, 664-70	15.7	229
402	Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. *Nature Genetics*, **2004**, 36, 687-93	36.3	379
401	Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. *Nature Immunology*, **2004**, 5, 74-80	19.1	1038
400	Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasis. *Nature Medicine*, **2004**, 10, 974-81	50.5	458
399	Vegfc is required for vascular development and endoderm morphogenesis in zebrafish. *EMBO Reports*, **2004**, 5, 78-84	6.5	86
398	Quantification of vascular endothelial growth factor-C (VEGF-C) by a novel ELISA. *Journal of Immunological Methods*, **2004**, 285, 145-55	2.5	34
397	Role of lymphangiogenic factors in tumor metastasis. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2004**, 1654, 3-12	11.2	73
396	An endostatin-derived peptide interacts with integrins and regulates actin cytoskeleton and migration of endothelial cells. *Journal of Biological Chemistry*, **2004**, 279, 20178-85	5.4	94
395	Immunodetection and quantification of vascular endothelial growth factor receptor-3 in human malignant tumor tissues. *International Journal of Cancer*, **2004**, 111, 184-91	7.5	38
394	Gene transfer into rabbit arteries with adeno-associated virus and adenovirus vectors. *Journal of Gene Medicine*, **2004**, 6, 545-54	3.5	53
393	Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. *Trends in Immunology*, **2004**, 25, 387-95	14.4	316
392	Plasmin activates VEGF-C and VEGF-D. *International Congress Series*, **2004**, 1262, 79-82		1
391	Origins of serum semicarbazide-sensitive amine oxidase. *Circulation Research*, **2004**, 95, 50-7	15.7	110
390	Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. *Blood*, **2004**, 104, 2084-6	2.2	350
389	PDGF-D induces macrophage recruitment, increased interstitial pressure, and blood vessel maturation during angiogenesis. *Blood*, **2004**, 104, 3198-204	2.2	128
388	Detection, Isolation and Culture of Lymphatic Endothelial Cells **2004**, 47-54		1
387	Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 8904-9	11.5	131
386	VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. *Journal of Cell Biology*, **2003**, 161, 1163-77	7.3	2122

385	p130Cas Couples the tyrosine kinase Bmx/Etk with regulation of the actin cytoskeleton and cell migration. *Journal of Biological Chemistry*, **2003**, 278, 35636-43	5.4	53
384	VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. *Circulation Research*, **2003**, 92, 1098-106	15.7	335
383	Vascular endothelial growth factor-D expression in human atherosclerotic lesions. *Cardiovascular Research*, **2003**, 59, 971-9	9.9	56
382	VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells. *Blood*, **2003**, 101, 168-72	2.2	315
381	Genesis and pathogenesis of lymphatic vessels. *Cell and Tissue Research*, **2003**, 314, 69-84	4.2	79
380	Matrix reloaded to circulation hits the tumor target. *Cancer Cell*, **2003**, 3, 513-4	24.3	8
379	Gene transfer as a tool to induce therapeutic vascular growth. *Nature Medicine*, **2003**, 9, 694-701	50.5	346
378	Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites. *Journal of Biological Chemistry*, **2003**, 278, 40973-9	5.4	187
377	Lymphangiogenic growth factors, receptors and therapies. *Thrombosis and Haemostasis*, **2003**, 90, 167-84		107
376	Endostatin associates with lipid rafts and induces reorganization of the actin cytoskeleton via down-regulation of RhoA activity. *Journal of Biological Chemistry*, **2003**, 278, 37895-901	5.4	100
375	Vascular endothelial growth factor (VEGF) receptor-2 signaling mediates VEGF-C(deltaNdeltaC)- and VEGF-A-induced angiogenesis in vitro. *Experimental Cell Research*, **2003**, 285, 286-98	4.2	37
374	Transcriptional regulation of the ornithine decarboxylase gene by c-Myc/Max/Mad network and retinoblastoma protein interacting with c-Myc. *International Journal of Biochemistry and Cell Biology* , **2003**, 35, 496-521	5.6	30
373	Angiogenic responses of vascular endothelial growth factors in periadventitial tissue. *Human Gene Therapy*, **2003**, 14, 1451-62	4.8	72
372	Angiopoietin-regulated recruitment of vascular smooth muscle cells by endothelial-derived heparin binding EGF-like growth factor. *FASEB Journal*, **2003**, 17, 1609-21	0.9	99
371	Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis. *Circulation*, **2003**, 107, 1308-14	16.7	85
370	Etk/Bmx transactivates vascular endothelial growth factor 2 and recruits phosphatidylinositol 3-kinase to mediate the tumor necrosis factor-induced angiogenic pathway. *Journal of Biological Chemistry*, **2003**, 278, 51267-76	5.4	118
369	Intrinsic versus microenvironmental regulation of lymphatic endothelial cell phenotype and function. *FASEB Journal*, **2003**, 17, 2006-13	0.9	66
368	Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D. *Journal of Experimental Medicine*, **2003**, 198, 863-8	16.6	161

367	The bloody fate of endothelial stem cells. *Genes and Development*, **2003**, 17, 322-9	12.6	39
366	Double target for tumor mass destruction. *Journal of Clinical Investigation*, **2003**, 111, 1277-1280	15.9	37
365	Double target for tumor mass destruction. *Journal of Clinical Investigation*, **2003**, 111, 1277-80	15.9	16
364	Vascular Endothelial Growth Factors and their Receptors in Vasculogenesis, Angiogenesis, and Lymphangiogenesis **2003**, 855-859		0
363	VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors. *International Journal of Cancer*, **2002**, 98, 946-51	7.5	178
362	FGFR4 overexpression in pancreatic cancer is mediated by an intronic enhancer activated by HNF1alpha. *Oncogene*, **2002**, 21, 8251-61	9.2	49
361	Lymphatic endothelium: a new frontier of metastasis research. *Nature Cell Biology*, **2002**, 4, E2-5	23.4	163
360	Lymphangiogenesis and cancer metastasis. *Nature Reviews Cancer*, **2002**, 2, 573-83	31.3	647
359	Insights into the molecular pathogenesis and targeted treatment of lymphedema. *Annals of the New York Academy of Sciences*, **2002**, 979, 94-110	6.5	42
358	Molecular mechanisms of lymphangiogenesis in health and disease. *Cancer Cell*, **2002**, 1, 219-27	24.3	576
357	Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. *EMBO Journal*, **2002**, 21, 4593-9	13	481
356	The transcription factor Prox1 is a marker for lymphatic endothelial cells in normal and diseased human tissues. *FASEB Journal*, **2002**, 16, 1271-3	0.9	154
355	Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 8868-73	11.5	261
354	Vascular endothelial growth factor enhances cardiac allograft arteriosclerosis. *Circulation*, **2002**, 105, 2524-30	16.7	116
353	Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. *Journal of the National Cancer Institute*, **2002**, 94, 819-25	9.7	425
352	Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes. *FASEB Journal*, **2002**, 16, 1041-9	0.9	134
351	A fluorescent Tie1 reporter allows monitoring of vascular development and endothelial cell isolation from transgenic mouse embryos. *FASEB Journal*, **2002**, 16, 1764-74	0.9	47
350	Vascular growth factors and lymphangiogenesis. *Physiological Reviews*, **2002**, 82, 673-700	47.9	322

349	Lymphangiogenic gene therapy with minimal blood vascular side effects. *Journal of Experimental Medicine*, **2002**, 196, 719-30	16.6	129
348	Therapeutic lymphangiogenesis with human recombinant VEGF-C. *FASEB Journal*, **2002**, 16, 1985-7	0.9	203
347	Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. *American Journal of Pathology*, **2002**, 160, 1405-23	5.8	495
346	Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. *American Journal of Pathology*, **2002**, 161, 947-56	5.8	628
345	Lymphatic endothelial regulation, lymphoedema, and lymph node metastasis. *Seminars in Cell and Developmental Biology*, **2002**, 13, 9-18	7.5	60
344	The angiogenic and lymphangiogenic factor vascular endothelial growth factor-D exhibits a paracrine mode of action in cancer. *Growth Factors*, **2002**, 20, 99-107	1.6	49
343	Dual role of Ang2 in postnatal angiogenesis and lymphangiogenesis. *Developmental Cell*, **2002**, 3, 302-4	10.2	41
342	Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. *Blood*, **2002**, 99, 2179-84	2.2	217
341	Abnormal lymphatic vessel development in neuropilin 2 mutant mice. *Development (Cambridge)*, **2002**, 129, 4797-4806	6.6	432
340	Molecular mechanisms of lymphangiogenesis. *Cold Spring Harbor Symposia on Quantitative Biology*, **2002**, 67, 189-96	3.9	12
339	Vascular endothelial growth factors C and D and their VEGFR-2 and 3 receptors in blood and lymphatic vessels in healthy and arthritic synovium. *Journal of Rheumatology*, **2002**, 29, 39-45	4.1	49
338	Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and podoplanin. *Investigative Ophthalmology and Visual Science*, **2002**, 43, 2127-35		135
337	Endostatin associates with integrin alpha5beta1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. *Cancer Research*, **2002**, 62, 5580-9	10.1	143
336	Abnormal lymphatic vessel development in neuropilin 2 mutant mice. *Development (Cambridge)*, **2002**, 129, 4797-806	6.6	199
335	Evidence of a leading role for VEGF in Bartonella henselae-induced endothelial cell proliferations. *Cellular Microbiology*, **2001**, 3, 623-32	3.9	135
334	Involvement of VEGFR-2 (kdr/flk-1) but not VEGFR-1 (flt-1) in VEGF-A and VEGF-C-induced tube formation by human microvascular endothelial cells in fibrin matrices in vitro. *Angiogenesis*, **2001**, 4, 53-60	10.6	50
333	Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. *EMBO Journal*, **2001**, 20, 4762-73	13	604
332	Net-targeted mutant mice develop a vascular phenotype and up-regulate egr-1. *EMBO Journal*, **2001**, 20, 5139-52	13	110

331	Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. *EMBO Journal*, **2001**, 20, 672-82	13	696
330	Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. *EMBO Journal*, **2001**, 20, 1223-31	13	543
329	Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. *Nature Medicine*, **2001**, 7, 192-8	50.5	1383
328	Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. *Nature Medicine*, **2001**, 7, 199-205	50.5	610
327	Tie receptors: new modulators of angiogenic and lymphangiogenic responses. *Nature Reviews Molecular Cell Biology*, **2001**, 2, 257-67	48.7	332
326	PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. *Nature Cell Biology*, **2001**, 3, 512-6	23.4	453
325	Novel p62dok family members, dok-4 and dok-5, are substrates of the c-Ret receptor tyrosine kinase and mediate neuronal differentiation. *Journal of Cell Biology*, **2001**, 154, 345-54	7.3	143
324	Bmx tyrosine kinase has a redundant function downstream of angiopoietin and vascular endothelial growth factor receptors in arterial endothelium. *Molecular and Cellular Biology*, **2001**, 21, 4647-55	4.8	67
323	Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin. *Circulation Research*, **2001**, 88, 623-9	15.7	189
322	Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. *Cardiovascular Research*, **2001**, 49, 659-70	9.9	223
321	A model for gene therapy of human hereditary lymphedema. *Proceedings of the National Academy of Sciences of the United States of America*, **2001**, 98, 12677-82	11.5	481
320	The specificity of receptor binding by vascular endothelial growth factor-d is different in mouse and man. *Journal of Biological Chemistry*, **2001**, 276, 19166-71	5.4	135
319	Interaction of endostatin with integrins implicated in angiogenesis. *Proceedings of the National Academy of Sciences of the United States of America*, **2001**, 98, 1024-1029	11.5	377
318	Multiple forms of mouse vascular endothelial growth factor-D are generated by RNA splicing and proteolysis. *Journal of Biological Chemistry*, **2001**, 276, 44307-14	5.4	54
317	Vascular endothelial growth factor-B-deficient mice display an atrial conduction defect. *Circulation*, **2001**, 104, 358-64	16.7	130
316	Chromosomal location, exon structure, and vascular expression patterns of the human PDGFC and PDGFD genes. *Circulation*, **2001**, 103, 2242-7	16.7	103
315	Vascular abnormalities and deregulation of VEGF in Lkb1-deficient mice. *Science*, **2001**, 293, 1323-6	33.3	239
314	Lymphatic vessels as targets of tumor therapy?. *Journal of Experimental Medicine*, **2001**, 194, F37-42	16.6	103

313	VEGFR3 gene structure, regulatory region, and sequence polymorphisms. *FASEB Journal*, **2001**, 15, 1028-36	6.9	59
312	Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. *American Journal of Pathology*, **2001**, 159, 893-903	5.8	329
311	The Drosophila VEGF receptor homolog is expressed in hemocytes. *Mechanisms of Development*, **2001**, 109, 69-77	1.7	89
310	Molecular regulation of lymphangiogenesis and targets for tissue oedema. *Trends in Molecular Medicine*, **2001**, 7, 18-22	11.5	53
309	VEGF-C/VEGFRS and Cancer Metastasis **2001**, 223-239		
308	Growth Factor Regulation of Physiologic Angiogenesis in the Mammary Gland **2001**, 25-40		
307	Interaction of endostatin with integrins implicated in angiogenesis. *Proceedings of the National Academy of Sciences of the United States of America*, **2001**, 98, 1024-9	11.5	190
306	VEGFR3 gene structure, regulatory region, and sequence polymorphisms. *FASEB Journal*, **2001**, 15, 1028-1034	6.9	5
305	Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. *Cancer Research*, **2001**, 61, 1786-90	10.1	435
304	Endostatin-induced modulation of plasminogen activation with concomitant loss of focal adhesions and actin stress fibers in cultured human endothelial cells. *Cancer Research*, **2001**, 61, 6511-6	10.1	51
303	VEGFs and Receptors in Angiogenesis and Lymphangiogenesis. *Biochemical Society Transactions*, **2000**, 28, A138-A138	5.1	
302	Amniotic Fluid Soluble Vascular Endothelial Growth Factor Receptor-1 in Preeclampsia. *Obstetrics and Gynecology*, **2000**, 95, 353-357	4.9	8
301	Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3. *FEBS Journal*, **2000**, 267, 2505-15		86
300	Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. *Nature Genetics*, **2000**, 25, 153-9	36.3	521
299	Developmental expression of pim kinases suggests functions also outside of the hematopoietic system. *Oncogene*, **2000**, 19, 1215-24	9.2	86
298	The Bmx tyrosine kinase is activated by IL-3 and G-CSF in a PI-3K dependent manner. *Oncogene*, **2000**, 19, 4151-8	9.2	34
297	Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. *Oncogene*, **2000**, 19, 6122-9	9.2	212
296	PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. *Nature Cell Biology*, **2000**, 2, 302-9	23.4	493

295	VEGF-C signaling pathways through VEGFR-2 and VEGFR-3 in vasculoangiogenesis and hematopoiesis. *Blood*, **2000**, 96, 3793-3800	2.2	125
294	Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis. *Blood*, **2000**, 96, 546-553	2.2	199
293	VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. *FASEB Journal*, **2000**, 14, 2087-96	0.9	272
292	Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta. *Circulation*, **2000**, 102, 2262-8	16.7	117
291	Vascular endothelial growth factor-C and its receptor VEGFR-3 in the nasal mucosa and in nasopharyngeal tumors. *American Journal of Pathology*, **2000**, 157, 7-14	5.8	37
290	Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. *American Journal of Pathology*, **2000**, 156, 1499-504	5.8	305
289	Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase. *American Journal of Human Genetics*, **2000**, 67, 295-301	11	338
288	Production and characterization of the extracellular domain of recombinant human fibroblast growth factor receptor 4. *International Journal of Biochemistry and Cell Biology*, **2000**, 32, 489-97	5.6	7
287	Amniotic fluid--soluble vascular endothelial growth factor receptor-1 in preeclampsia. *Obstetrics and Gynecology*, **2000**, 95, 353-7	4.9	87
286	VEGF-C signaling pathways through VEGFR-2 and VEGFR-3 in vasculoangiogenesis and hematopoiesis. *Blood*, **2000**, 96, 3793-3800	2.2	3
285	Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis. *Blood*, **2000**, 96, 546-553	2.2	25
284	Kaposi Sarkome sind positiv f□ VEGFR-3 und Podoplanin: Ein erster direkter Beweis f□ die Abstammung dieses Tumors vom lymphatischen Endothel **2000**, 351-354		
283	Growth factors regulating lymphatic vessels. *Current Topics in Microbiology and Immunology*, **2000**, 251, 75-82	3.3	12
282	Regulation of angiogenesis via vascular endothelial growth factor receptors. *Cancer Research*, **2000**, 60, 203-12	10.1	481
281	Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis. *Blood*, **2000**, 96, 546-53	2.2	58
280	Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. *Cancer Research*, **2000**, 60, 4324-7	10.1	317
279	An avian model for studies of embryonic lymphangiogenesis. *Lymphology*, **2000**, 33, 81-94	1.9	23
278	VEGF-C signaling pathways through VEGFR-2 and VEGFR-3 in vasculoangiogenesis and hematopoiesis. *Blood*, **2000**, 96, 3793-800	2.2	43

277	Role of ets factors in the activity and endothelial cell specificity of the mouse Tie gene promoter. *FASEB Journal*, **1999**, 13, 377-86	0.9	89
276	Vascular endothelial growth factor is bound in amniotic fluid and maternal serum. *Human Reproduction*, **1999**, 14, 1346-51	5.7	42
275	Endothelial growth factor receptors in human fetal heart. *Circulation*, **1999**, 100, 583-6	16.7	50
274	Vascular endothelial growth factor (VEGF) and VEGF-C show overlapping binding sites in embryonic endothelia and distinct sites in differentiated adult endothelia. *Circulation Research*, **1999**, 85, 992-9	15.7	59
273	Vascular endothelial growth factor-C stimulates the migration and proliferation of KaposiR sarcoma cells. *Journal of Biological Chemistry*, **1999**, 274, 27617-22	5.4	75
272	Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers. *Journal of Biological Chemistry*, **1999**, 274, 32127-36	5.4	255
271	Identification of Tek/Tie2 binding partners. Binding to a multifunctional docking site mediates cell survival and migration. *Journal of Biological Chemistry*, **1999**, 274, 30896-905	5.4	159
270	Distribution of human herpesvirus-8 latently infected cells in KaposiR sarcoma, multicentric CastlemanR disease, and primary effusion lymphoma. *Proceedings of the National Academy of Sciences of the United States of America*, **1999**, 96, 4546-51	11.5	584
269	Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1. *Journal of Biological Chemistry*, **1999**, 274, 21217-22	5.4	215
268	Vascular endothelial growth factor-C (VEGF-C) and its receptors KDR and flt-4 are expressed in AIDS-associated KaposiR sarcoma. *Journal of Investigative Dermatology*, **1999**, 113, 1047-53	4.3	91
267	Current biology of VEGF-B and VEGF-C. *Current Opinion in Biotechnology*, **1999**, 10, 528-35	11.4	137
266	Clinical applications of angiogenic growth factors and their inhibitors. *Nature Medicine*, **1999**, 5, 1359-64	50.5	878
265	Endothelial receptor tyrosine kinases activate the STAT signaling pathway: mutant Tie-2 causing venous malformations signals a distinct STAT activation response. *Oncogene*, **1999**, 18, 1-8	9.2	119
264	c-Myc and E1A induced cellular sensitivity to activated NK cells involves cytotoxic granules as death effectors. *Oncogene*, **1999**, 18, 2181-8	9.2	11
263	Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis. *British Journal of Cancer*, **1999**, 80, 309-13	8.7	230
262	VEGFs, receptors and angiogenesis. *Seminars in Cancer Biology*, **1999**, 9, 211-20	12.7	389
261	Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors **1999**, 86, 2406-2412		198
260	Localization of VEGF-B in the mouse embryo suggests a paracrine role of the growth factor in the developing vasculature. *Developmental Dynamics*, **1999**, 215, 12-25	2.9	75

259	Vascular endothelial growth factor (VEGF)-like protein from orf virus NZ2 binds to VEGFR2 and neuropilin-1. *Proceedings of the National Academy of Sciences of the United States of America*, **1999**, 96, 3071-6	11.5	228
258	Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells. *Molecular and Cellular Endocrinology*, **1999**, 149, 29-40	4.4	185
257	Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. *American Journal of Pathology*, **1999**, 155, 421-8	5.8	437
256	Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. *American Journal of Pathology*, **1999**, 154, 385-94	5.8	886
255	VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. *American Journal of Pathology*, **1999**, 154, 1381-90	5.8	447
254	Lymphatic endothelial tumors induced by intraperitoneal injection of incomplete Freund® adjuvant. *Experimental Cell Research*, **1999**, 246, 368-75	4.2	62
253	Signaling via vascular endothelial growth factor receptors. *Experimental Cell Research*, **1999**, 253, 117-30	4.2	225
252	Prognostic value of tumour vascularity in metastatic melanoma and association of blood vessel density with vascular endothelial growth factor expression. *Melanoma Research*, **1999**, 9, 59-68	3.3	66
251	Structure, expression and receptor-binding properties of novel vascular endothelial growth factors. *Current Topics in Microbiology and Immunology*, **1999**, 237, 41-57	3.3	115
250	Vascular endothelial growth factor receptor-3. *Current Topics in Microbiology and Immunology*, **1999**, 237, 85-96	3.3	52
249	Papillary intralymphatic angioendothelioma (PILA): a report of twelve cases of a distinctive vascular tumor with phenotypic features of lymphatic vessels. *American Journal of Surgical Pathology*, **1999**, 23, 1004-10	6.7	122
248	Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors **1999**, 86, 2406		5
247	Localization of VEGF-B in the mouse embryo suggests a paracrine role of the growth factor in the developing vasculature **1999**, 215, 12		1
246	Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi® sarcoma tumor cells. *Laboratory Investigation*, **1999**, 79, 243-51	5.9	68
245	Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. *Cancer*, **1999**, 86, 2406-12	6.4	58
244	Co-amplification of a novel cyclophilin-like gene (PPIE) with L-myc in small cell lung cancer cell lines. *Oncogene*, **1998**, 17, 1019-26	9.2	21
243	Vascular endothelial growth factor-C: a growth factor for lymphatic and blood vascular endothelial cells. *Trends in Cardiovascular Medicine*, **1998**, 8, 292-7	6.9	37
242	Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity. *Journal of Cellular Physiology*, **1998**, 177, 439-52	7	134

241	Similarities between TNF and exogenous oxidants on the cytotoxic response of c-Myc-expressing fibroblasts in vitro. *Cancer Letters*, **1998**, 125, 191-8	9.9	5
240	Signaling angiogenesis and lymphangiogenesis. *Current Opinion in Cell Biology*, **1998**, 10, 159-64	9	155
239	Endothelial tie receptor antigen in maternal and cord blood of healthy and preeclamptic subjects. *Obstetrics and Gynecology*, **1998**, 92, 179-83	4.9	11
238	Analysis of patients with craniosynostosis syndromes for a pro246Arg mutation of FGFR4. *Molecular Genetics and Metabolism*, **1998**, 64, 76-9	3.7	6
237	Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. *American Journal of Pathology*, **1998**, 153, 103-8	5.8	268
236	Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors. *American Journal of Pathology*, **1998**, 153, 395-403	5.8	170
235	Is angiopoietin-2 necessary for the initiation of tumor angiogenesis?. *American Journal of Pathology* , **1998**, 153, 1333-9	5.8	75
234	Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. *Science*, **1998**, 282, 946-9	33.3	646
233	Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. *Journal of Biological Chemistry*, **1998**, 273, 8413-8	5.4	296
232	A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities. *Journal of Biological Chemistry*, **1998**, 273, 6599-602	5.4	181
231	Vascular endothelial growth factor C induces angiogenesis in vivo. *Proceedings of the National Academy of Sciences of the United States of America*, **1998**, 95, 14389-94	11.5	465
230	Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. *Proceedings of the National Academy of Sciences of the United States of America*, **1998**, 95, 11709-14	11.5	438
229	Overexpression of VEGF in testis and epididymis causes infertility in transgenic mice: evidence for nonendothelial targets for VEGF. *Journal of Cell Biology*, **1998**, 143, 1705-12	7.3	93
228	Endothelial Tie Receptor Antigen in Maternal and Cord Blood of Healthy and Preeclamptic Subjects. *Obstetrics and Gynecology*, **1998**, 92, 179-183	4.9	7
227	Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). *Proceedings of the National Academy of Sciences of the United States of America*, **1998**, 95, 548-53	11.5	970
226	Peripheral Blood Platelets Express VEGF-C and VEGF which Are Released during Platelet Activation. *Thrombosis and Haemostasis*, **1998**, 80, 171-175	7	230
225	Avian VEGF-C: cloning, embryonic expression pattern and stimulation of the differentiation of VEGFR2-expressing endothelial cell precursors. *Development (Cambridge)*, **1998**, 125, 743-752	6.6	44
224	Avian VEGF-C: cloning, embryonic expression pattern and stimulation of the differentiation of VEGFR2-expressing endothelial cell precursors. *Development (Cambridge)*, **1998**, 125, 743-52	6.6	13

223	Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. *Cancer Research*, **1998**, 58, 1599-604	10.1	213
222	Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. *Thrombosis and Haemostasis*, **1998**, 80, 171-5	7	67
221	Expression of vascular endothelial growth factor and placenta growth factor in human placenta. *Biology of Reproduction*, **1997**, 56, 489-94	3.9	208
220	Identification of csk tyrosine phosphorylation sites and a tyrosine residue important for kinase domain structure. *Biochemical Journal*, **1997**, 322 (Pt 3), 927-35	3.8	12
219	Genomic organization of human and mouse genes for vascular endothelial growth factor C. *Journal of Biological Chemistry*, **1997**, 272, 25176-83	5.4	133
218	VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. *Developmental Biology*, **1997**, 188, 96-109	3.1	398
217	Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. *Science*, **1997**, 276, 1423-5	33.3	1056
216	The Bmx Tyrosine Kinase Induces Activation of the Stat Signaling Pathway, Which Is Specifically Inhibited by Protein Kinase C□*Blood*, **1997**, 90, 4341-4353	2.2	97
215	Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. *Oncogene*, **1997**, 14, 2475-83	9.2	382
214	Proteolytic processing regulates receptor specificity and activity of VEGF-C. *EMBO Journal*, **1997**, 16, 3898-911	13	613
213	Induction of TNF-sensitive cellular phenotype by c-Myc involves p53 and impaired NF-kappaB activation. *EMBO Journal*, **1997**, 16, 7382-92	13	87
212	A molecular and genetic analysis of renalglomerular capillary development. *Angiogenesis*, **1997**, 1, 84-101	10.6	58
211	Analysis of Tie receptor tyrosine kinase in haemopoietic progenitor and leukaemia cells. *British Journal of Haematology*, **1997**, 98, 195-203	4.5	53
210	Vascular endothelial growth factors VEGF-B and VEGF-C. *Journal of Cellular Physiology*, **1997**, 173, 211-5	7	106
209	Bmx tyrosine kinase is specifically expressed in the endocardium and the endothelium of large arteries. *Circulation*, **1997**, 96, 1729-32	16.7	57
208	The Bmx Tyrosine Kinase Induces Activation of the Stat Signaling Pathway, Which Is Specifically Inhibited by Protein Kinase C□*Blood*, **1997**, 90, 4341-4353	2.2	6
207	BCL2 Overexpression Associated With Chromosomal Amplification in Diffuse Large B-Cell Lymphoma. *Blood*, **1997**, 90, 1168-1174	2.2	2
206	Vascular endothelial growth factors VEGF-B and VEGF-C **1997**, 173, 211		3

205	The Bmx tyrosine kinase induces activation of the Stat signaling pathway, which is specifically inhibited by protein kinase Cdelta. *Blood*, **1997**, 90, 4341-53	2.2	30
204	Genomic organization of the mouse and human genes for vascular endothelial growth factor B (VEGF-B) and characterization of a second splice isoform. *Journal of Biological Chemistry*, **1996**, 271, 19310-7	5.4	142
203	BMX tyrosine kinase gene is expressed in granulocytes and myeloid leukaemias. *British Journal of Haematology*, **1996**, 94, 455-460	4.5	29
202	The Tie receptor tyrosine kinase is expressed by human hematopoietic progenitor cells and by a subset of megakaryocytic cells. *Blood*, **1996**, 87, 2212-2220	2.2	61
201	A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.. *EMBO Journal*, **1996**, 15, 1751-1751	13	300
200	Expression of growth factors and growth factor receptors in capillary hemangioblastoma. *Journal of Neuropathology and Experimental Neurology*, **1996**, 55, 522-7	3.1	63
199	Tie endothelial cell-specific receptor tyrosine kinase is upregulated in the vasculature of arteriovenous malformations. *Journal of Neuropathology and Experimental Neurology*, **1996**, 55, 1124-33	3.1	77
198	Endothelial Tie growth factor receptor provides antigenic marker for assessment of breast cancer angiogenesis. *British Journal of Cancer*, **1996**, 74, 69-72	8.7	38
197	Vascular endothelial growth factor B, a novel growth factor for endothelial cells. *Proceedings of the National Academy of Sciences of the United States of America*, **1996**, 93, 2576-81	11.5	597
196	A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.. *EMBO Journal*, **1996**, 15, 290-298	13	951
195	Association of a 85-kDa serine kinase with activated fibroblast growth factor receptor-4. *Journal of Biological Chemistry*, **1996**, 271, 1270-3	5.4	28
194	Novel human vascular endothelial growth factor genes VEGF-B and VEGF-C localize to chromosomes 11q13 and 4q34, respectively. *Circulation*, **1996**, 93, 1079-82	16.7	67
193	VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. *Development (Cambridge)*, **1996**, 122, 3829-3837	6.6	440
192	A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. *EMBO Journal*, **1996**, 15, 290-98	13	348
191	Vascular growth factors and receptors in capillary hemangioblastomas and hemangiopericytomas. *American Journal of Pathology*, **1996**, 148, 763-75	5.8	84
190	Molecular Mechanisms Controlling Susceptibitliy to Tumor Necrosis Factor Induced Cell Death **1996** , 143-154		
189	The Tie receptor tyrosine kinase is expressed by human hematopoietic progenitor cells and by a subset of megakaryocytic cells. *Blood*, **1996**, 87, 2212-20	2.2	16
188	BMX tyrosine kinase gene is expressed in granulocytes and myeloid leukaemias. *British Journal of Haematology*, **1996**, 94, 455-60	4.5	18

187	VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. *Development (Cambridge)*, **1996**, 122, 3829-37	6.6	148
186	Endothelial-specific gene expression directed by the tie gene promoter in vivo. *Blood*, **1995**, 86, 1828-1835	11.2	134
185	Mechanically stretched chromosomes as targets for high-resolution FISH mapping. *Genome Research*, **1995**, 5, 13-20	9.7	24
184	Expression of the mad gene during cell differentiation in vivo and its inhibition of cell growth in vitro. *Journal of Cell Biology*, **1995**, 128, 1197-208	7.3	99
183	Androgen and fibroblast growth factor (FGF) regulation of FGF receptors in S115 mouse mammary tumor cells. *Endocrinology*, **1995**, 136, 2179-88	4.8	33
182	Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. *Proceedings of the National Academy of Sciences of the United States of America*, **1995**, 92, 3566-70	11.5	1141
181	Identification of YAC clones for human chromosome 1p32 and physical mapping of the infantile neuronal ceroid lipofuscinosis (INCL) locus. *Genomics*, **1995**, 25, 404-12	4.3	24
180	Visual mapping by fiber-FISH. *Genomics*, **1995**, 30, 31-6	4.3	70
179	Overexpressed Csk tyrosine kinase is localized in focal adhesions, causes reorganization of alpha v beta 5 integrin, and interferes with HeLa cell spreading. *Molecular and Cellular Biology*, **1995**, 15, 711-22	4.8	109
178	Endothelial receptor tyrosine kinases involved in angiogenesis. *Journal of Cell Biology*, **1995**, 129, 895-8	7.3	467
177	The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells.. *EMBO Journal*, **1995**, 14, 5884-5891	13	358
176	Vascularization of the mouse embryo: a study of flk-1, tek, tie, and vascular endothelial growth factor expression during development. *Developmental Dynamics*, **1995**, 203, 80-92	2.9	422
175	Cell transformation by c-Ha-rasVal12 oncogene is accompanied by a decrease in histone H1 zero and an increase in nucleosomal repeat length. *Journal of Cellular Biochemistry*, **1995**, 57, 1-11	4.7	14
174	Endothelial-specific gene expression directed by the tie gene promoter in vivo. *Blood*, **1995**, 86, 1828-35	2.2	32
173	The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. *EMBO Journal*, **1995**, 14, 5884-91	13	136
172	Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors. *American Journal of Pathology*, **1995**, 146, 368-78	5.8	137
171	Flt4: Flt4 receptor PTK (vertebrates) **1995**, 168-169		
170	c-Myc induces cellular susceptibility to the cytotoxic action of TNF-alpha.. *EMBO Journal*, **1994**, 13, 5442-5450	13	108

169	Rapid and efficient purification of Src homology 2 domain-containing proteins: Fyn, Csk and phosphatidylinositol 3-kinase p85. *Biochemical Journal*, **1994**, 302 (Pt 3), 737-44	3.8	35
168	Tyrosine phosphorylation of CD45 phosphotyrosine phosphatase by p50csk kinase creates a binding site for p56lck tyrosine kinase and activates the phosphatase. *Molecular and Cellular Biology*, **1994**, 14, 1308-21	4.8	134
167	Repression of cyclin D1: a novel function of MYC. *Molecular and Cellular Biology*, **1994**, 14, 4032-43	4.8	238
166	The mouse tie receptor tyrosine kinase gene: expression during embryonic angiogenesis. *Oncogene* , **1994**, 9, 395-403	9.2	91
165	Signal transduction by fibroblast growth factor receptor-4 (FGFR-4). Comparison with FGFR-1. *Journal of Biological Chemistry*, **1994**, 269, 18320-6	5.4	90
164	Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors. *Oncogene*, **1994**, 9, 3545-55	9.2	101
163	BMX, a novel nonreceptor tyrosine kinase gene of the BTK/ITK/TEC/TXK family located in chromosome Xp22.2. *Oncogene*, **1994**, 9, 3683-8	9.2	131
162	Enhanced expression of the tie receptor tyrosine kinase mesenger RNA in the vascular endothelium of metastatic melanomas. *Cancer Research*, **1994**, 54, 6571-7	10.1	89
161	Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. *Journal of Biological Chemistry*, **1994**, 269, 6271-4	5.4	462
160	Repression of cyclin D1: a novel function of MYC. *Molecular and Cellular Biology*, **1994**, 14, 4032-4043	4.8	112
159	Myc protein: partners and antagonists. *Critical Reviews in Oncogenesis*, **1994**, 5, 59-68	1.3	29
158	c-Myc induces cellular susceptibility to the cytotoxic action of TNF-alpha. *EMBO Journal*, **1994**, 13, 5442-50	5.9	32
157	Signal transduction by fibroblast growth factor receptor-4 (FGFR-4). Comparison with FGFR-1. *Journal of Biological Chemistry*, **1994**, 269, 18320-18326	5.4	100
156	Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells.. *Journal of Biological Chemistry*, **1994**, 269, 6271-6274	5.4	474
155	Tyrosine phosphorylation of CD45 phosphotyrosine phosphatase by p50csk kinase creates a binding site for p56lck tyrosine kinase and activates the phosphatase. *Molecular and Cellular Biology*, **1994**, 14, 1308-1321	4.8	44
154	Modulation of fibroblast growth factor receptor expression and signalling during retinoic acid-induced differentiation of Tera-2 teratocarcinoma cells. *Biochemical and Biophysical Research Communications*, **1993**, 191, 149-56	3.4	18
153	Fibroblast growth factor-mediated growth regulation and receptor expression in embryonal carcinoma and embryonic stem cells and human germ cell tumours. *Biochemical and Biophysical Research Communications*, **1993**, 191, 188-95	3.4	30
152	Refined assignment of the infantile neuronal ceroid lipofuscinosis (INCL, CLN1) locus at 1p32: incorporation of linkage disequilibrium in multipoint analysis. *Genomics*, **1993**, 16, 720-5	4.3	60

151	The human TYRO3 gene and pseudogene are located in chromosome 15q14-q25. *Gene*, **1993**, 134, 289-93	3.8	16
150	Structural and functional specificity of FGF receptors. *Philosophical Transactions of the Royal Society B: Biological Sciences*, **1993**, 340, 297-303	5.8	40
149	The related FLT4, FLT1, and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells. *Journal of Experimental Medicine*, **1993**, 178, 2077-88	16.6	215
148	Enhanced bFGF gene expression in response to transforming growth factor-beta stimulation of AKR-2B cells. *Growth Factors*, **1993**, 9, 81-6	1.6	20
147	A sub-set of immediate early mRNAs induced by tumor necrosis factor-alpha during cellular cytotoxic and non-cytotoxic responses. *International Journal of Cancer*, **1993**, 55, 655-9	7.5	4
146	FLT4 receptor tyrosine kinase gene mapping to chromosome band 5q35 in relation to the t(2;5), t(5;6), and t(3;5) translocations. *Genes Chromosomes and Cancer*, **1993**, 7, 144-51	5	18
145	Myc amplification: regulation of myc function. *Clinica Chimica Acta*, **1993**, 217, 57-62	6.2	5
144	Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. *Oncogene*, **1993**, 8, 925-31	9.2	204
143	Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative processing of primary transcripts. *Oncogene*, **1993**, 8, 2931-7	9.2	66
142	Role of myc amplification and overexpression in cell growth, differentiation and death. *Seminars in Cancer Biology*, **1993**, 4, 3-12	12.7	60
141	A chimeric EGFR/neu receptor in functional analysis of the neu oncoprotein. *Acta Oncologica*, **1992**, 31, 147-50	3.2	7
140	A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains. *Molecular and Cellular Biology*, **1992**, 12, 1698-707	4.8	290
139	Complex intrachromosomal rearrangement in the process of amplification of the L-myc gene in small-cell lung cancer. *Molecular and Cellular Biology*, **1992**, 12, 1747-54	4.8	11
138	Diverse receptors for fibroblast growth factors. *Progress in Growth Factor Research*, **1992**, 4, 69-83		96
137	An Alu variable polyA repeat polymorphism upstream of L-myc at 1p32. *Human Molecular Genetics*, **1992**, 1, 217	5.6	40
136	Alternative forms of Max as enhancers or suppressors of Myc-ras cotransformation. *Science*, **1992**, 256, 373-7	33.3	120
135	Plasmid pLTRpoly: a versatile high-efficiency mammalian expression vector. *Gene*, **1992**, 118, 293-4	3.8	20
134	A radiation hybrid map of 18 growth factor, growth factor receptor, hormone receptor, or neurotransmitter receptor genes on the distal region of the long arm of chromosome 5. *Genomics*, **1992**, 13, 803-8	4.3	78

133	The human p50csk tyrosine kinase phosphorylates p56lck at Tyr-505 and down regulates its catalytic activity.. *EMBO Journal*, **1992**, 11, 2919-2924	13	241
132	The c-src tyrosine kinase (CSK) gene, a potential antioncogene, localizes to human chromosome region 15q23----q25. *Cytogenetic and Genome Research*, **1992**, 60, 119-20	1.9	11
131	Fibroblast growth factor receptor-4 shows novel features in genomic structure, ligand binding and signal transduction.. *EMBO Journal*, **1992**, 11, 4273-4280	13	126
130	Amplification and rearrangement of L-myc in human small-cell lung cancer. *Mutation Research - Reviews in Genetic Toxicology*, **1992**, 276, 307-15		13
129	Localization of the fibroblast growth factor receptor-4 gene to chromosome region 5q33-qter. *Genes Chromosomes and Cancer*, **1992**, 4, 94-8	5	14
128	Analysis of tyrosine kinase mRNAs including four FGF receptor mRNAs expressed in MCF-7 breast-cancer cells. *International Journal of Cancer*, **1992**, 50, 598-603	7.5	43
127	FLT4, a novel class III receptor tyrosine kinase in chromosome 5q33-qter. *Cancer Research*, **1992**, 52, 746-8	10.1	70
126	Rearrangement and co-amplification of L-myc and rlf in primary lung cancer. *Oncogene*, **1992**, 7, 405-9	9.2	4
125	FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines. *Cancer Research*, **1992**, 52, 5738-43	10.1	183
124	Enhanced expression of the tie receptor tyrosine kinase in endothelial cells during neovascularization. *Blood*, **1992**, 80, 2548-55	2.2	34
123	A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains. *Molecular and Cellular Biology*, **1992**, 12, 1698-1707	4.8	99
122	Enhanced expression of the tie receptor tyrosine kinase in endothelial cells during neovascularization. *Blood*, **1992**, 80, 2548-2555	2.2	76
121	The human p50csk tyrosine kinase phosphorylates p56lck at Tyr-505 and down regulates its catalytic activity. *EMBO Journal*, **1992**, 11, 2919-24	13	93
120	Fibroblast growth factor receptor-4 shows novel features in genomic structure, ligand binding and signal transduction. *EMBO Journal*, **1992**, 11, 4273-80	13	41
119	Five FGF receptors with distinct expression patterns. *Exs*, **1992**, 61, 91-100		5
118	A chimeric EGFR/neu receptor in studies of neu function. *Cancer Treatment and Research*, **1992**, 61, 213-38	3.5	
117	Enhanced expression of the tie receptor tyrosine kinase in endothelial cells during neovascularization. *Blood*, **1992**, 80, 2548-2555	2.2	0
116	Intrachromosomal rearrangements fusing L-myc and rlf in small-cell lung cancer. *Molecular and Cellular Biology*, **1991**, 11, 4015-21	4.8	17

115	Constitutively activated neu oncoprotein tyrosine kinase interferes with growth factor-induced signals for gene activation. *Journal of Cellular Biochemistry*, **1991**, 45, 69-81	4.7	6
114	Estrogen suppression of erbB2 expression is associated with increased growth rate of ZR-75-1 human breast cancer cells in vitro and in nude mice. *International Journal of Cancer*, **1991**, 49, 616-23	7.5	49
113	Down-regulation of cellular platelet-derived growth factor receptors induced by an activated neu receptor tyrosine kinase. *Molecular Biology of the Cell*, **1991**, 2, 651-61		4
112	RFLPs in the fibroblast growth factor receptor-4 locus (FGFR4) in 5q33-qter. *Nucleic Acids Research*, **1991**, 19, 5096	20.1	6
111	UV damage and repair in the domain of the human c-myc oncogene. *DNA and Cell Biology*, **1991**, 10, 125-37	3.6	5
110	Immediate early gene responses of NIH 3T3 fibroblasts and NMuMG epithelial cells to TGF beta-1. *Growth Factors*, **1991**, 5, 283-93	1.6	16
109	Tumour markers and oncogenes in lung cancer. *European Journal of Cancer & Clinical Oncology*, **1991**, 27, 1323-7		7
108	Novel human FGF receptors with distinct expression patterns. *Annals of the New York Academy of Sciences*, **1991**, 638, 403-5	6.5	9
107	A fusion protein formed by L-myc and a novel gene in SCLC.. *EMBO Journal*, **1991**, 10, 1331-1335	13	21
106	FGFR-4, a novel acidic fibroblast growth factor receptor with a distinct expression pattern.. *EMBO Journal*, **1991**, 10, 1347-1354	13	388
105	Nuclear colocalization of cellular and viral myc proteins with HSP70 in myc-overexpressing cells. *Journal of Virology*, **1991**, 65, 842-51	6.6	49
104	A fusion protein formed by L-myc and a novel gene in SCLC. *EMBO Journal*, **1991**, 10, 1331-5	13	10
103	FGFR-4, a novel acidic fibroblast growth factor receptor with a distinct expression pattern. *EMBO Journal*, **1991**, 10, 1347-54	13	126
102	Intrachromosomal rearrangements fusing L-myc and rlf in small-cell lung cancer. *Molecular and Cellular Biology*, **1991**, 11, 4015-4021	4.8	6
101	Regulation by EGF is maintained in an overexpressed chimeric EGFR/neu receptor tyrosine kinase. *Journal of Cellular Biochemistry*, **1990**, 42, 123-33	4.7	11
100	c-Ha-rasVal 12 oncogene-transformed NIH-3T3 fibroblasts display more decondensed nucleosomal organization than normal fibroblasts. *Journal of Cell Biology*, **1990**, 111, 9-17	7.3	37
99	Increased erythroid potentiating activity/tissue inhibitor of metalloproteinases and jun/fos transcription factor complex characterize tumor promoter-induced megakaryoblastic differentiation of K562 leukemia cells. *Blood*, **1990**, 75, 1974-1982	2.2	34
98	Putative tyrosine kinases expressed in K-562 human leukemia cells. *Proceedings of the National Academy of Sciences of the United States of America*, **1990**, 87, 8913-7	11.5	96

97	Regulation by TGF□bf Genes Involved in Growth Control: Interleukin-6a. *Annals of the New York Academy of Sciences*, **1990**, 593, 318-320	6.5	3
96	Similar early gene responses to ligand-activated EGFR and neu tyrosine kinases in NIH3T3 cells. *Oncogene*, **1990**, 5, 615-8	9.2	15
95	Downregulation of the early genomic growth factor response in neu oncogene-transformed cells. *Oncogene*, **1990**, 5, 815-21	9.2	7
94	Expression of the myc proto-oncogenes in developing human fetal brain. *Oncogene*, **1990**, 5, 1787-97	9.2	40
93	Increased erythroid potentiating activity/tissue inhibitor of metalloproteinases and jun/fos transcription factor complex characterize tumor promoter-induced megakaryoblastic differentiation of K562 leukemia cells. *Blood*, **1990**, 75, 1974-1982	2.2	1
92	The cellular response to induction of the p21 c-Ha-ras oncoprotein includes stimulation of jun gene expression.. *EMBO Journal*, **1989**, 8, 815-822	13	73
91	Rapid phosphorylation of the L-myc protein induced by phorbol ester tumor promoters and serum.. *EMBO Journal*, **1989**, 8, 149-157	13	24
90	The N-myc proto-oncogene and IGF-II growth factor mRNAs are expressed by distinct cells in human fetal kidney and brain. *Journal of Cell Biology*, **1989**, 108, 1093-104	7.3	55
89	A chimeric EGF-R-neu proto-oncogene allows EGF to regulate neu tyrosine kinase and cell transformation.. *EMBO Journal*, **1989**, 8, 159-166	13	58
88	Activation of the neu tyrosine kinase induces the fos/jun transcription factor complex, the glucose transporter and ornithine decarboxylase. *Journal of Cell Biology*, **1989**, 109, 1911-9	7.3	70
87	Oncogene expression in small-cell lung cancer cell lines and a testicular germ-cell tumor: activation of the N-myc gene and decreased RB mRNA. *International Journal of Cancer*, **1989**, 44, 182-5	7.5	19
86	Transforming growth factor-beta does not alter interleukin-1 expression in cultured human macrophages. *Journal of Cellular Biochemistry*, **1989**, 39, 467-75	4.7	6
85	The methylation pattern of normal and truncated amplified human c-myc oncogenes. *Biochimica Et Biophysica Acta Gene Regulatory Mechanisms*, **1989**, 1007, 350-5		3
84	Mechanism of T cell proliferation in vivo: analysis of IL-2 receptor expression and activation of c-myc and c-myb oncogenes during lymphatic regeneration. *Biochemical and Biophysical Research Communications*, **1989**, 160, 181-8	3.4	3
83	Interleukin-2 induces a rapid increase in ornithine decarboxylase mRNA in a cloned murine T lymphocytic cell line. *Experimental Cell Research*, **1989**, 181, 273-81	4.2	14
82	Receptor downregulation and DNA synthesis are modulated by EGF and TPA in cells expressing an EGFR/neu chimera. *Growth Factors*, **1989**, 1, 323-34	1.6	6
81	Two N-myc polypeptides with distinct amino termini encoded by the second and third exons of the gene. *Molecular and Cellular Biology*, **1989**, 9, 1545-52	4.8	30
80	Enhanced jun gene expression is an early genomic response to transforming growth factor beta stimulation. *Molecular and Cellular Biology*, **1989**, 9, 1255-62	4.8	227

79	Activation of an EGFR/neu chimeric receptor: early intracellular signals and cell proliferation responses. *Oncogene*, **1989**, 4, 1299-305	9.2	23
78	Enhanced jun gene expression is an early genomic response to transforming growth factor beta stimulation. *Molecular and Cellular Biology*, **1989**, 9, 1255-1262	4.8	67
77	Two N-myc polypeptides with distinct amino termini encoded by the second and third exons of the gene. *Molecular and Cellular Biology*, **1989**, 9, 1545-1552	4.8	10
76	Rapid phosphorylation of the L-myc protein induced by phorbol ester tumor promoters and serum. *EMBO Journal*, **1989**, 8, 149-57	13	8
75	A chimeric EGF-R-neu proto-oncogene allows EGF to regulate neu tyrosine kinase and cell transformation. *EMBO Journal*, **1989**, 8, 159-66	13	36
74	The cellular response to induction of the p21 c-Ha-ras oncoprotein includes stimulation of jun gene expression. *EMBO Journal*, **1989**, 8, 815-22	13	42
73	Expression of the c-Ha-ras and neu oncogenes in DMBA-induced, anti-estrogen-treated rat mammary tumors. *International Journal of Cancer*, **1988**, 42, 774-9	7.5	18
72	Growth Factors, Oncogenes and Cancer. *Scandinavian Journal of Clinical and Laboratory Investigation*, **1988**, 48, 32-34	2	
71	Enhanced expression of transforming growth factor beta during megakaryoblastic differentiation of K562 leukemia cells. *Blood*, **1988**, 71, 899-906	2.2	31
70	Enhanced expression of TGF-beta and c-fos mRNAs in the growth plates of developing human long bones. *Development (Cambridge)*, **1988**, 102, 461-70	6.6	28
69	The mechanisms of ornithine decarboxylase deregulation in c-Ha-ras oncogene-transformed NIH 3T3 cells. *Journal of Biological Chemistry*, **1988**, 263, 4500-7	5.4	94
68	The mechanisms of ornithine decarboxylase deregulation in c-Ha-ras oncogene-transformed NIH 3T3 cells.. *Journal of Biological Chemistry*, **1988**, 263, 4500-4507	5.4	83
67	Enhanced expression of transforming growth factor beta during megakaryoblastic differentiation of K562 leukemia cells. *Blood*, **1988**, 71, 899-906	2.2	
66	Mouse and human ornithine decarboxylase genes. Methylation polymorphism and amplification. *Biochemical Journal*, **1987**, 242, 205-10	3.8	23
65	Regulation of platelet-derived growth factor gene expression by transforming growth factor beta and phorbol ester in human leukemia cell lines. *Molecular and Cellular Biology*, **1987**, 7, 3656-62	4.8	69
64	Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis. *Proceedings of the National Academy of Sciences of the United States of America*, **1987**, 84, 8548-52	11.5	105
63	Dose effects of transfected c-Ha-rasVal 12 oncogene in transformed cell clones. *Experimental Cell Research*, **1987**, 168, 518-30	4.2	59
62	Induction of platelet-derived growth factor gene expression during megakaryoblastic and monocytic differentiation of human leukemia cell lines.. *EMBO Journal*, **1987**, 6, 1213-1218	13	46

61	myc oncogenes: activation and amplification. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **1987**, 907, 1-32	11.2	44
60	Regulation of platelet-derived growth factor gene expression by transforming growth factor beta and phorbol ester in human leukemia cell lines. *Molecular and Cellular Biology*, **1987**, 7, 3656-3662	4.8	20
59	Induction of platelet-derived growth factor gene expression during megakaryoblastic and monocytic differentiation of human leukemia cell lines. *EMBO Journal*, **1987**, 6, 1213-8	13	22
58	Rearrangement at the 5Rend of amplified c-myc in human COLO 320 cells is associated with abnormal transcription. *Molecular and Cellular Biology*, **1986**, 6, 2752-5	4.8	31
57	Oncogene amplification in tumor cells. *Advances in Cancer Research*, **1986**, 47, 235-81	5.9	270
56	Human ornithine decarboxylase sequences map to chromosome regions 2pter----p23 and 7cen----qter but are not coamplified with the NMYC oncogene. *Cytogenetic and Genome Research*, **1986**, 42, 133-40	1.9	46
55	Rearrangement at the 5Rend of amplified c-myc in human COLO 320 cells is associated with abnormal transcription. *Molecular and Cellular Biology*, **1986**, 6, 2752-2755	4.8	12
54	Evolution of karyotypic abnormalities and C-MYC oncogene amplification in human colonic carcinoma cell lines. *Chromosoma*, **1985**, 92, 11-5	2.8	57
53	Amplification and enhanced expression of the c-myc oncogene in mouse SEWA tumour cells. *Nature*, **1985**, 315, 345-7	50.4	68
52	Evidence for p15 cleavage site in myc-specific proteins of avian MC29 and OK10 viruses. *Journal of Cellular Biochemistry*, **1985**, 28, 265-72	4.7	1
51	Acute myelogenous leukaemia with c-myc amplification and double minute chromosomes. *Lancet, The*, **1985**, 2, 1035-9	40	75
50	Amplification of cellular oncogenes in cancer cells. *Trends in Biochemical Sciences*, **1985**, 10, 194-197	10.3	27
49	Mapping of amplified c-myb oncogene, sister chromatid exchanges, and karyotypic analysis of the COLO 205 colon carcinoma cell line. *Cancer Genetics and Cytogenetics*, **1985**, 18, 251-64		15
48	Reorganization of plasma membrane-associated 36 000 dalton protein upon drug-induced redistribution of cytokeratin. *Experimental Cell Research*, **1985**, 158, 86-94	4.2	11
47	Amplification of the c-myc oncogene in a subpopulation of human small cell lung cancer. *Cancer Research*, **1985**, 45, 1823-7	10.1	53
46	Amplification of ornithine decarboxylase gene in response to polyamine deprivation in Chinese hamster ovary cells. *Journal of Biological Chemistry*, **1985**, 260, 8532-7	5.4	33
45	Amplification of ornithine decarboxylase gene in response to polyamine deprivation in Chinese hamster ovary cells.. *Journal of Biological Chemistry*, **1985**, 260, 8532-8537	5.4	35
44	Retroviruses in Neoplasia Yesterday, Today and Tomorrow **1985**, 3-17		

43	Amplification of Cellular Oncogenes in Colon and Lung Cancer Cells **1985**, 485-495		
42	The myc proteins are not associated with chromatin in mitotic cells.. *EMBO Journal*, **1984**, 3, 2947-2950	13	28
41	Transformation of cultured epithelial cells by ethylnitrosourea. Altered expression of type I procollagen chains. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **1984**, 803, 153-62	4.9	4
40	Distribution of the 36 000 dalton tyrosine protein kinase substrate in drug and epidermal growth factor-treated epithelial cells. *Experimental Cell Research*, **1984**, 150, 177-85	4.2	4
39	Aberrant expression of an amplified c-myb oncogene in two cell lines from a colon carcinoma. *Proceedings of the National Academy of Sciences of the United States of America*, **1984**, 81, 4534-8	11.5	147
38	The myc proteins are not associated with chromatin in mitotic cells. *EMBO Journal*, **1984**, 3, 2947-50	13	12
37	Effects of Zn2+ ions on protein phosphorylation in epithelial cell membranes. *Journal of Cellular Physiology*, **1983**, 115, 305-12	7	22
36	Subcellular location of an abundant substrate (p36) for tyrosine-specific protein kinases. *Molecular and Cellular Biology*, **1983**, 3, 340-50	4.8	105
35	Nucleotide sequence to the v-myc oncogene of avian retrovirus MC29. *Proceedings of the National Academy of Sciences of the United States of America*, **1983**, 80, 100-4	11.5	165
34	Homogeneously staining chromosomal regions contain amplified copies of an abundantly expressed cellular oncogene (c-myc) in malignant neuroendocrine cells from a human colon carcinoma. *Proceedings of the National Academy of Sciences of the United States of America*, **1983**, 80, 1707-11	11.5	633
33	The p36 substrate of tyrosine-specific protein kinases co-localizes with non-erythrocyte alpha-spectrin antigen, p230, in surface lamina of cultured fibroblasts.. *EMBO Journal*, **1983**, 2, 1701-1705	13	46
32	A cellular oncogene (c-Ki-ras) is amplified, overexpressed, and located within karyotypic abnormalities in mouse adrenocortical tumour cells. *Nature*, **1983**, 303, 497-501	50.4	432
31	Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. *Nature*, **1983**, 305, 245-8	50.4	1170
30	Identification of nuclear proteins encoded by viral and cellular myc oncogenes. *Nature*, **1983**, 306, 274-7	50.4	224
29	Biosynthesis of an unusual collagen type by human astrocytoma cells in vitro.. *Journal of Biological Chemistry*, **1983**, 258, 2653-2661	5.4	47
28	Pericellular matrix in malignant transformation. *Advances in Cancer Research*, **1982**, 37, 111-58	5.9	88
27	Extracellular matrix proteins of human epidermal keratinocytes and feeder 3T3 cells. *Journal of Cell Biology*, **1982**, 94, 497-505	7.3	114
26	Regulation of proline 3-hydroxylation and prolyl 3-hydroxylase and 4-hydroxylase activities in transformed cells. *Biochemical Journal*, **1982**, 206, 499-503	3.8	4

25	Loss of different pericellular matrix components of rat cells transformed with a T-class ts mutant of Rous sarcoma virus. *Virology*, **1982**, 119, 347-57	3.6	27
24	Basal lamina glycoproteins laminin and type IV collagen are assembled into a fine-fibered matrix in cultures of a teratocarcinoma-derived endodermal cell line. *Experimental Cell Research*, **1982**, 137, 15-23	4.2	45
23	Deposition of an intermediate form of procollagen type III (pN-collagen) into fibrils in the matrix of amniotic epithelial cells.. *EMBO Journal*, **1982**, 1, 47-52	13	16
22	Deposition of basement membrane proteins in attachment and neurite formation of cultured murine C-1300 neuroblastoma cells. *Journal of Cellular Biochemistry*, **1982**, 18, 25-35	4.7	32
21	Endo- and ectocervical human uterine epithelial cells distinguished by fibronectin production and keratinization in culture. *Cancer Research*, **1982**, 42, 1142-6	10.1	8
20	Pericellular matrix and cell surface glycoproteins of virus-transformed mouse epithelial cells. *Cancer Research*, **1982**, 42, 1147-53	10.1	11
19	Deposition of an intermediate form of procollagen type III (pN-collagen) into fibrils in the matrix of amniotic epithelial cells. *EMBO Journal*, **1982**, 1, 47-52	13	2
18	Biosynthesis of type V procollagen by A204, a human rhabdomyosarcoma cell line.. *Journal of Biological Chemistry*, **1982**, 257, 9016-9024	5.4	36
17	Posttranslational modifications in the biosynthesis of type IV collagen by a human tumor cell line. *Biochemistry*, **1981**, 20, 7409-15	3.2	42
16	Regulation of collagen post-translational modification in transformed human and chick-embryo cells. *Biochemical Journal*, **1981**, 196, 683-92	3.8	24
15	Extracellular matrix proteins characterize human tumor cell lines. *International Journal of Cancer*, **1981**, 27, 755-61	7.5	75
14	Basal lamina components in experimentally induced skin blisters. *Journal of Investigative Dermatology*, **1981**, 77, 283-6	4.3	30
13	Induction of a basement membrane glycoprotein in embryonic kidney: possible role of laminin in morphogenesis. *Proceedings of the National Academy of Sciences of the United States of America*, **1980**, 77, 485-9	11.5	250
12	Basal lamina glycoproteins are produced by neuroblastoma cells. *Nature*, **1980**, 287, 465-6	50.4	64
11	Biosynthesis of two subunits of type IV procollagen and of other basement membrane proteins by a human tumor cell line. *FEBS Journal*, **1980**, 109, 247-55		134
10	Fibronectin is produced by human macrophages. *Journal of Experimental Medicine*, **1980**, 151, 602-13	16.6	272
9	Extracellular matrix components synthesized by human amniotic epithelial cells in culture. *Cell*, **1980**, 19, 1053-62	56.2	132
8	Production of both interstitial and basement membrane procollagens by fibroblastic WI-38 cells from human embryonic lung. *Biochemical and Biophysical Research Communications*, **1980**, 93, 873-80	3.4	35

7	Type III procollagen is the major collageneous component produced by a continuous rhabdomyosarcoma cell line. *FEBS Letters*, **1979**, 104, 405-9	3.8	53
6	Fibronectin and procollagen produced by a clonal line of Schwann cells. *FEBS Letters*, **1979**, 102, 64-8	3.8	25
5	Fibronectin in the development of embryonic chick eye. *Developmental Biology*, **1979**, 69, 589-600	3.1	107
4	Isolation of the pericellular matrix of human fibroblast cultures. *Journal of Cell Biology*, **1979**, 81, 83-91	7.3	258
3	Fibronectin and the pericellular matrix of normal and transformed adherent cells. *Annals of the New York Academy of Sciences*, **1978**, 312, 343-53	6.5	49
2	Clear-cell sarcoma of tendons and aponeuroses. Report of two cases. *Acta Orthopaedica*, **1977**, 48, 241-4		9
1	PROX1 transcription factor is a master regulator of myogenic and oncogenic features of rhabdomyosarcoma		1